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CHAPTER I 
Introduction 
 
 
1.1 c-Myc: the origins 
In 1911 Peyton Rous observed that chicken sarcoma could be transmitted through cell-
free extracts from the tumors, suggesting that a virus could be the etiologic agent of these 
sarcomas. On the basis of the work by Bishop and coworkers, studies of a specific 
subgroup of avian retrovirus, which induces myeloid leukemia, sarcomas, liver, kidney, 
and other tumors in chickens, led to the identification of the v-myc oncogene. Its cellular 
homolog, the c-myc gene, was discovered more than 20 years ago (Crews et al., 1982; 
Dalla-Favera et al., 1982). 
The c-myc gene is located on human chromosome 8q24. It was discovered soon after its 
identification that activated oncogenic c-MYC was instrumental in the progression of 
human Burkitt’s lymphoma, as a result of a translocation between chromosome 8 and one 
of the three chromosomes that contain antibody-encoding genes (Taub et al., 1982; Dalla-
Favera et al., 1982). Elevated or deregulated expression of c-MYC has been detected in a 
wide range of human cancers, and is often associated with aggressive, poorly 
differentiated tumours. Such cancers include breast, colon, cervical, small-cell lung 
carcinomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemias (Dang, 
1999; Nesbit et al., 1999) 
 
1.2 Who is c-Myc 
Four transcriptional promoters have been identified, but RNA initiated at the P2 promoter 
usually contributes to 80-90% of total c-myc steady-state RNA in normal cells (Taub et 
al., 1984). A shift in the transcription starting point has been documented in Burkitt's cell 
lines, where transcription of the translocated c-myc is preferentially initiated further 
upstream at promoter P1 instead of at P2 (Strobl and Eick, 1992; Strobl et al., 1993; Taub 
et al., 1984). The cause of this promoter shift is not known. 
The c-myc gene comprises three exons. Exon 1 contains two promoters and is non 
coding. Exons 2 and 3 encode the Myc protein resulting in the the major 64-kDa 
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polypeptide with translation initiation at the canonical AUG start codon nucleotide 16 of 
exon 2. A longer polypeptide of 67 kDa results from translation initiated 15 codons 
upstream of the AUG at a CUG codon (exon 1) (Hann et al., 1992). An internal 
translationally initiated c-Myc 45-kDa polypeptide was recently recognized (Spotts et al., 
1997). 
In mammals, there are four related genes in the family, c-Myc, N-Myc, L-Myc and S-Myc. 
A fifth gene, B-Myc, encodes a protein that shows significant homology to the N 
terminus, but lacks essential domains in the C terminus, of the other Myc proteins, and its 
biology is poorly understood (Levens et al., 2002,; Eisenman, 2001). The N-terminal 143 
amino acids and the C-terminal 140 amino acids of c-Myc are required for neoplastic 
transformation and inhibition of cellular differentiation (Dang, 1999). These two regions 
correspond to the N-terminal transactivation domain and the C-terminal DNA-binding 
and HLHzip dimerization domain The N terminus of Myc has three highly conserved 
elements, known as Mycboxes. Of these, MycboxI has been implicated in Myc turnover 
(Bahram et al., 2000). MycboxIII also regulates protein stability but is essential for Myc 
function in vivo, and is required for full transactivation and transrepression of many target 
genes (Herbst et al., 2004, 2005). Most attention has focused on understanding the 
function of MycboxII, the second Mycbox in the N terminus of Myc, as it is required for 
all the known biological functions of Myc. MycboxII is not involved in the binding of 
Myc to Max or to DNA, but is required for activation and repression of most, but not all, 
Myc target genes. Immediately N-terminal to the dimerization domain there is a domain 
rich in basic amino acids which directly contacts specific DNA sequences within the 
DNA major groove (Dang et al., 1992; Dong et al., 1994; Ferre-D’Amare et al., 1993) 
(Figure 1). 
 
1.3 c-Myc and friends (molecular partners) 
Several proteins can bind directly to MycboxII, raising the question of whether they bind 
simultaneously or whether Myc forms separate complexes with each of these proteins. 
One is TRRAP, which is a core subunit of the TIP60 and GCN5 Histone Acetyl 
Transferase (HAT) complexes (McMahon et al., 1998) and the recruitment depends on 
the integrity of MycboxII (Bouchard et al., 2001; Frank et al., 2001). Most probably,  
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therefore, transcriptional activation of some target genes depends on the recruitment of 
HAT activity by Myc. TRRAP is also part of a complex containing the p400 E1A-
binding protein, which is devoid of HAT activity (Fuchs et al., 2001). This second 
complex is also found in association with Myc, which indicates that the Myc–TRRAP 
interaction has other roles in addition to the recruitment of HAT activity. Such roles 
might include the capacity to exchange histones, in particular histone H2A (Kusch T et 
al., 2004). 
Two other proteins that are found in the TIP60 complex bind to MycboxII independently 
of TRRAP; these are TIP48 and TIP49, two highly conserved hexameric ATPases (Wood 
et al., 2000). Both proteins are found in several chromatin remodelling complexes. The 
Xenopus homologues of TIP48 and TIP49 have recently been implicated in 
transcriptional repression by the Myc–Miz1 complex (Etard et al.,2005). 
MycboxII is required for interaction with SKP2 of the E3 ubiquitin ligase, SCFSKP2, and 
Myc recruits SKP2 to its target genes in vivo (Kim et al., 2003; von der Lehr et al., 2003). 
Recruitment of SKP2 is required for the transactivation of several Myc target genes. 
Surprisingly, Myc is also a substrate of SKP2, which indicates that ubiquitylation of Myc 
might be required for transcriptional activation. Ubiquitylation by SCFSKP2 probably 
allows Myc to recruit proteasomal subunits that have a role in transcriptional activation 
that is proteolysis independent. 
As mentioned above, not all Myc target genes require the integrity of MycboxII for 
activation, which shows that there are other mechanisms of Myc-dependent activation 
and, most likely, repression. For example, CREB-binding protein (CBP) and p300 have 
been identified as other histone acetyl transferases that interact with Myc and that are 
recruited to target genes in vivo. Both interact with the C terminus of Myc, which shows 
that the classic separation of Myc domains into DNA-binding and transcriptional-effector 
domains might be obsolete.  
Also Brca1 interacts with the C terminus of Myc and inhibits its transcriptional and 
transforming activity in cells (Wang et al., 1998). 
In vivo, Myc recruits Mediator complexes to its target promoters in a MycboxII-
independent manner (Bouchard et al., 2004). The same is true for cyclin-dependent 
kinase-9 (CDK9), a subunit of the positive transcription elongation factor b (P-TEFb) 
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complex (Kanazawa et al., 2003). In vitro, both Mediator and P-TEFb complexes bind to 
the extreme N terminus of Myc. 
Finally, Myc recruits a DNA methyltransferase, DNMT3a, to the Myc–Miz1 complex, 
indicating that Myc-dependent gene repression could at least partly be mediated by 
methylation of its target promoters (Brenner et al., 2005). 
 
1.4 c-Myc regulation 
c-Myc activity is normally tightly controlled, at transcription level, by external signals 
including growth factors, mitogens and β-catenin, which promote and factors such as 
TGF-β, which inhibit. Its expression also undergoes a negative autoregulatory circuit 
(Grignani et al., 1990; Lombardi et al., 1990; Penn et al., 1990): expression of one c-Myc 
allele leads to the downregulation of the other. The normal c-myc allele is usually 
transcriptionally silent in Burkitt's lymphomas (ar-Rushdi et al., 1983; Cory, 1986; 
Hayday et al., 1984; Nishikura et al., 1983), and thus the only Myc protein in most 
Burkitt's cells is derived from the translocated c-myc allele; as well mice constitutively 
expressing a transgenic allele, downregulate the endogenous gene. This autoregulation is 
active in normal and immortalized cells derived from multiple tissues, but is inactivated 
in fully transformed tumor cells (Grignani et al., 1990). 
In its physiological role, c-MYC is broadly expressed during embryogenesis and in tissue 
compartments of the adult that possess high proliferative capacity (such as skin epidermis 
and gut). Its expression strongly correlates with cell proliferation. In quiescent cells in 
vitro, c-myc expression is virtually undetectable. However, after mitogenic or serum 
stimulation, c-myc mRNA and protein are rapidly induced and cells enter the G1 phase of 
the cell cycle. Thereafter, the mRNA and protein decline to low, but detectable, steady-
state levels in proliferating cells. If serum or growth factors are removed, c-MYC levels 
decline to undetectable levels and cells arrest. Temporal regulation of c-Myc protein 
accumulation is essential for normal cell proliferation. 
c-Myc protein is stabilized after activation of Ras, allowing it to accumulate to high 
levels (Sears et al., 1999). Ras promotes stability of c-Myc through at least two effector 
pathways: the Raf–MEK–ERK kinase cascade, and the phosphatidylinositol-3-OH kinase 
(PI(3)K)–Akt pathway that inhibits glycogen synthase kinase-3β(GSK-3β) (Figure 2).  
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The ERK and GSK-3β kinases phosphorylate two sites near the amino terminus of c-Myc 
that are highly conserved in all mammalian c-Myc isoforms. These phosphorylation sites, 
Thr 58 and Ser 62, exert opposing control on c-Myc degradation through the ubiquitin-
proteasome pathway (Sears et al., 2000). Thus, after a growth stimulatory signal, c-myc 
gene transcription is increased and newly synthesized c-Myc protein is phosphorylated on 
Ser 62, via the Raf–MEK–ERK pathway, resulting in its stabilization. . Phosphorylation 
at Ser 62 is also required for the subsequent phosphorylation of c-Myc at Thr 58 by GSK-
3β, which is associated with c-Myc degradation (Sears et al., 2000; Pulverer et al 1994). 
During early G1 phase, however, GSK-3β activity is regulated by Ras-mediated 
activation of the PI(3)K/Akt pathway (which phosphorylates and inhibits GSK-3β), 
facilitating stabilization of c-Myc. Later in G1 phase, Ras activity declines after cessation 
of the growth stimulus, PI(3)K and Akt activities also decline, resulting in reactivation of 
GSK-3βand phosphorylation of c-Myc on Thr 58 which is important for c-Myc turnover. 
Phosphorylation of Thr 58 is important for recognition of c-Myc by the Pin1 prolyl 
isomerase. Pin1 facilitates c-Myc dephosphorylation at Ser 62 by PP2A, which then 
promotes c-Myc turnover by the ubiquitin-proteasome pathway through E3 ligase 
SCFFBW7 that recognizes Phospho-Thr 58. Thus, the very mechanism that stabilizes and 
amplifies c-Myc accumulation — c-Myc phosphorylation at Ser 62 — also triggers the 
subsequent phosphorylation at Thr 58 and the series of events that culminate in 
degradation of c-Myc. 
Considerable evidence suggests that Thr 58 phosphorylation is critical for ensuring the 
transient and timely degradation of c-Myc. All v-myc genes recovered in transforming 
retroviruses harbour mutation at Thr 58. Similarly, a large number of c-myc genes 
amplified in Burkitt’s lymphoma carry a mutation at Thr 58, as well as in other residues 
between amino acids 57 and 63 (Pulverer et al., 1994; Henriksson et al., 1993; Salghetti 
et al., 1999). Assay of these mutants generally demonstrates their increased oncogenic 
potential in both cell transformation assays and animals (Chang et al., 2000). In example  
the c-MycT58A mutant is no longer a substrate for ubiquitination in vivo (Sears et al., 
2000)  and replaces SV40 small T antigen, which inhibits the protein phosphatase-2A 
(PP2A) and is a strong activator of PI3K, in transforming human fibroblasts in the 
presence of SV40 large T antigen (SV40T) and telomerase (Yeh et al., 2004). 
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Another mechanism by witch Ras regulates Myc activity is through the FOXO family 
transcription factors (Bouchard et al. 2004). In their non-phosphorylated state, FOXO 
factors directly bind to and repress many Myc target genes that are involved in cell 
proliferation by inhibiting the formation of the preinitiation complex on these genes. 
Following Ras activation, the PI3K pathway leads to the AKT-dependent 
phosphorylation of FOXO proteins and their nuclear export mediated by binding to the 
14-3-3 protein. Moreover also the DNA-binding domain of Miz1 is a target for 
phosphorylation by the AKT kinase (Wanzel et al., 2005). After phosphorylation, 14-3-3 
PROTEINS bind to Miz1 and inhibit DNA binding and transcriptional activation of 
p21CIP1. As a result, the activation of AKT cooperates with Myc in compromising the 
ability of Miz1 to inhibit cell proliferation. 
These post-translational controls of Myc function partially explain the requirement for 
Ras in cellular transformation induced by Myc. 
 
1.5 The c-Myc network 
No monomeric Myc proteins have been found in vivo. Instead, Myc is bound to a partner 
protein, Max, through a basic-region/helix–loop–helix/leucine-zipper (BR/HLH/LZ) 
domain (Blackwood et al., 1991, 1992). Max is present in stoichiometric excess to Myc, 
due to e constitutive gene expression and high stability at mRNA and protein level. Max 
is now recognized as the central and shared dimerization partner of a rather large network 
of related b-HLH-Zip transcription factors that function, as transcriptional repressors 
(Grandori et al., 2000) Indeed it can also form homodimers or heterodimers with several 
related proteins, known as Mad1, Mxi1 (also known as Mad2), Mad3, Mad4 and Mnt 
(also known as Rox), as shown by in vitro binding experiments (Ayer and Eisenman., 
1993; Hurlin et al., 1996,1997). The dimers all bind directly to the same DNA sequence 
(CACA/GTG), which is a subset of the general E-box sequence (CANNTG) that is bound 
by all bHLH proteins (Blackwell et al., 1990). In vivo, Myc–Max complexes activate 
transcription through interactions with transcriptional coactivators (such as TRRAP and 
BAF53) and their associated histone acetyltransferases (HATs, e.g., GCN5) and/ or 
ATPase helicases (TIPs, e.g., TIP49) (McMahon et al., 1998, 2000; Dugan et al., 2002) 
and are often predominant in proliferating cells (Figure 3). Instead Mad–Max or Mnt– 
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Max complexes are predominant in resting or differentiated cells (Ayer and Eisenman., 
1993) where actively repress transcription through direct protein-protein interactions with 
the general transcriptional corepressors Sin3a-3b (Ayer et al., 1995) and, with Sin3's 
corepressors (e.g., N-Cor and the SkiSno proteins) and histone deacetylases (HDACs) 
(Alland et al., 1997; Heinzel et al., 1997). Histone deacetylation is currently thought to be 
the major mode of transcriptional silencing by the Mad proteins. The Sin3-intacting 
domain motif, when tethered to an HLH/LZ transcriptional factor, TFEB, that binds Myc 
DNA sites, is able to inhibit c-Myc-mediated cellular transformation (Harper et al., 
1996). 
Detailed knowledge about the amino-acid residues that dictate leucine-zipper interactions 
has made it possible to design reciprocal mutants of Myc and Max that heterodimerize 
with each other, but not with the endogenous proteins (Amati et al., 1993). The analysis 
of these mutants shows that binding to Max is required for the transforming properties of 
Myc and the ability of Myc to induce cell-cycle progression and apoptosis. Not 
surprisingly, heterodimerization with Max is required for the binding of Myc to DNA. 
Surprisingly, however, this is true not only for the E-box sequence, to which the Myc–
Max heterodimer binds directly, but also for the ‘non-consensus’ binding sites to which 
Myc is recruited through protein–protein interactions with other DNA binding factors 
(Mao, 2003). One potential explanation for this finding is that binding to Max might be 
required for the correct folding of the Myc protein. 
A second surprising finding is that Myc and Max exist as an antiparallel tetramer in the 
crystal structure; tetramerization is mediated by interactions between specific amino acids 
on the ‘outside’ of the Myc and Max leucine zippers (Nair and Burley, 2003). The 
dissociation constant is so low that even the few Myc–Max complexes present in normal 
cells are expected to exist as tetramers in vivo. 
When bound to E-box sequences, Myc–Max heterodimers activate transcription, whereas 
Mad–Max and Mnt–Max heterodimers repress transcription (Ayer et al., 1993, Hurlin et 
al., 1997). Several experiments have addressed the biological significance of this model. 
For example, if transcriptional activation is the key biological function of Myc, the model 
predicts that knockout of the Mad or Mnt repressor proteins should have a similar 
biological effect as the overexpression of Myc. Indeed, deletion of Mnt in primary mouse 
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embryonic fibroblasts induces proliferation in the absence of Myc, and mammary 
carcinomas develop in Mnt–/– animals (Nilsson et al., 2004; Hurlin et al., 2003). 
Similarly, deletion of Mad1 delays the terminal differentiation of granulocytes, and 
deletion of Mxi1 enhances proliferation in several cell types (Schreiber-Agus et al., 1998; 
Foley et al., 1998). However, there is little evidence that Mad or Mnt proteins function as 
tumour suppressor proteins in human tumours. Therefore, interactions of the HLH 
domain with proteins other than Max contribute to the biological function of Myc. One 
such protein is Miz1, a zinc-finger protein that binds to the ‘outside’ of the helix–loop–
helix domain of Myc, but does not interact with Max, Mad or any other Myc family 
members (Herold et al., 2002; Peukert et al., 1997). 
 
1.6 c-Myc target genes 
The advent of technologies to study in vivo DNA-binding sites of Myc has yielded a 
number of important advances as well as surprises in the field. The known gene targets of 
MYC, however, have been far more difficult to assign to pathways that have obvious 
links to cellcycle progression or malignant transformation. Furthermore, none of the 
known targets of Myc, including the gene encoding cyclin D2, are able to completely 
substitute for any specific Myc function (Berns et al., 2000). In addition to its role in 
regulating cell proliferation, c-myc products regulate cell mass (Iritani and Eisenman, 
1999; Johnston et al., 1999; Shuhmacher et al., 1999). Although a link between an 
increase in cell mass and cell-cycle progression has been known for many years, the 
direct mechanism by which these are related is not understood (Conlon and Raff, 1999). 
Myc has been shown to control many genes encoding products that regulate ribosome 
biogenesis and protein translation, which can ultimately affect cell mass and 
proliferation. 
Several recent studies have shaken paradigm this, the model that Myc behaves like other 
transcription factors to regulate a handful of specific genes. In these studies Myc has been 
shown to bind not a few, but to thousands of potential target genes (Li et al., 2003; Mao 
et al., 2003; Fernandez et al., 2003; orian et al., 2003). 10–25% of the Myc targets that 
are identified are repressed rather than activated (Zeller et al., 2003). 
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In early studies, putative gene targets of Myc were identified by empirical methods 
(Dang, 1999). Typically, these studies identified a role for Myc either based on the 
function of the putative target or because the promoter region of the target gene contained 
a potential binding site for Myc. 
Recently, different microarray-based screens have added over 600 genes to the list of 
potential Myc targets (Coller et al., 2000). This number might be artificially high, as most 
of the microarray screens do not distinguish between direct and indirect targets of Myc. 
In a few cases, a third approach to identifying Myc targets has been used. This approach 
has relied on screens for genes that can compensate for loss of Myc function. With a few 
notable exceptions, these kinds of studies have not identified genes that have obvious 
links to the biological processes typically associated with Myc function (for example, 
cell-cycle progression, malignant transformation and apoptosis). 
Several groups have recently published important studies aimed at more precise 
identification of the genes that are regulated by Myc. These efforts were based on the 
wellfounded assumption that Myc, like most other transcription factors, simply binds to 
specific genes and alters their levels of transcription. The somewhat surprising result 
from some of these studies is that Myc only alters transcription levels of a minority of the 
genes it binds to. Fernandez and co-workers have performed a large-scale analysis of 
Myc binding to promoters that contain the E-box consensus element CACGTG in live 
human cells (Fernandez et al., 2003). As in the accompanying study of Drosophila Myc 
(Orian et al. 2003), the data reveal that the protein associates with a strikingly large 
number of genomic loci, suggesting significant diversity in the ensuing transcriptional 
response. The conserved core of high-affinity Myc-target genes represents roughly 11% 
of all cellular promoters. This number of target genes is most likely an underestimate, 
because the screen performed by Fernandez and co-workers was based solely on the 
“canonical” E-box element CACGTG, whereas another E-box (CACATG or CATGTG) 
and variant sites (e.g., CACGCG) can also be bound by Myc/Max (Grandori et al. 2000; 
Oster et al. 2002). A second reason is that Myc and Max are recruited to non-consensus 
binding sites through the interaction with other transcription factors. One example of 
such a ‘tethering factor’ is Miz1, which can recruit Myc and Max to core promoter 
sequences that lack a CACGTG sequence (Herold et al., 2002; Mao et al., 2003). So, 
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there is a class of core promoters at which both Myc and Miz1 are bound in vivo (Wanzel 
et al., 2005). As some core promoters have been found at which Myc, but not Miz1, is 
bound, there must be other proteins that recruit Myc to their cognate DNA-binding sites 
(Barsyte-Lovejoy et al., 2004). 
The direct binding of Myc to such a large number of sites both in humans and Drosophila 
(Orian et al. 2003) was not anticipated and is not a general feature of eukaryotic 
transcription factors. The Myc-binding patterns that we have observed in our cell lines 
suggest that target sites in chromatin compete for limiting Myc protein levels. The peak 
expression of Myc in serum-stimulated human fibroblasts has been estimated at 3–6000 
molecules per cell (mpc), whereas cycling cells expressed 1–3000 mpc. Thus, there may 
rarely, if ever, be enough Myc in normal cells to bind all potential targets, assuming that 
11% of cellular genes means >4000 target loci (Hogenesch et al. 2002), many of which 
possess multiple E-boxes. 
The analysis also included a small number of promoters that did not contain E-boxes. In 
cells with high levels of endogenous Myc, only 7% of non-E-box promoters were 
occupied. When Myc was ectopically expressed in cells, however, it bound to almost 
100% of E-box-containing genes. Surprisingly, ectopic expression of Myc caused it to 
bind to 88% of these non-E-box promoters. 
Among the best predictors of whether a given E-box would be occupied by Myc was its 
proximity to a CpG island (Fernandez et al., 2003). The Fernandez and co-workers also 
observed that the chromatin around the Myc-bound loci was highly acetylated, even 
before Myc binding. This was unexpected, as Myc has been shown to recruit histone 
acetyltransferase enzymes. These results indicate that Myc might preferentially bind to 
genes that have a chromatin structure that is already poised for transcription. Equally 
puzzling, an examination of the Myc-target-gene database reveals that only a minority 
(10.4%) of Myc bound genes show a transcriptional response to Myc activation (Zeller et 
al., 2003). 
Myc, Max and Mnt were each shown to bind to a large number of genes that were not 
bound by the other family members (Orian et al., 2003). In fact, only about 34% (96/287) 
of the genes that bound to Myc were also found to be bound by its partner Max.  
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In another study Li et al. examined Myc binding to proximal promoter regions of 4,839 
genes in a Burkitt’s lymphoma cell line (Li et al., 2003). They demonstrated that Myc 
bound to 876 of these genes (~15%), 776 of which were also bound by Max. However, 
comparing this data to the Myc-target-gene database, only 68 of the 876 Myc-bound loci 
(7.8%) have been reported to be Myc-responsive genes. 
These studies indicate that Myc binding to a given gene might not always correlate well 
with its level of transcription. So not all Myc-bound genes are necessarily effectors of 
Myc function. Moreover, many loci to which Myc is bound in vivo are not located close 
to a protein-coding gene. Myc also regulates transcription of both RNA polymerase III 
(RNA pol III)-dependent genes and RNA-pol-I-dependent, ribosomal RNA genes, and 
binds to the promoters of these genes in vivo (Grewal et al., 2005; Grandori et al., 2005; 
Arabi et al., 2005). Finally, DNA-binding sites of Myc are found 5′to the transcription 
start site of a novel class of non-coding RNA molecules, for which no catalytic function 
has been identified so far. Myc might therefore also regulate these non-coding RNAs, and 
the biological significance of this finding as well as the function of these RNAs remain to 
be determined. 
 
1.7 c-Myc functions in Cell Growth and Proliferation  
Targeted gene disruption of both c-Myc alleles in embryonic stem cells leads to 
embryonic lethality at day 9.5–10.5 with a lack of primitive hematopoiesis, which 
highlights the crucial role of c-Myc in normal growth control during mammalian 
development. And in Drosophila reduced expression of the orthologue dmyc results in 
smaller but developmentally normal flies and his level of expression directly correlates 
with the cell size (Johnston et al., 1999), while in Eµ-Myc transgenic mice its 
overexpression results in cell growth in the absence of cell-cycle progression (Iritani et 
al., 1999; Shuhmacher et al., 1999). 
c-Myc transcripts are detected in a wide variety of tissues during development. In the 
mid-gestation mouse, enhanced c-Myc expression correlates well with active 
proliferation, and its downregulation accompanies mitotic arrest and onset of 
differentiation (Schmid et al., 1989). 
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More recently, the cell-cycle effects of ablating c-Myc have been investigated. A rat 
fibroblast cell line in which both alleles were ablated shows greatly reduced rates of cell 
proliferation, accompanied by cell-cycle defects in G1 that include significantly delayed 
phosphorylation of the retinoblastoma protein (Rb) (Mateyak et al.,1997). Intriguingly Rb 
phosphorilation occured when c-Myc-deficient cell reached the same size as control cells. 
The first notion that c-Myc influenced cell growth came from the correlation between c-
Myc and the expression of the rate-limiting translation initiation factors eIF4E and eIF2α 
(Rosenwald et al., 1993), which are now known to be direct c-Myc targets (Coller et 
al.,2000). Important information is accumulating as to how c-MYC may be mediating 
effects on cell growth. RNA polymerase III (pol III) is involved in the generation of 
transfer RNA and 5S ribosomal RNA required for protein synthesis in growing cells and 
is activated by c-MYC via binding to TFIIIB, a pol III-specific general transcription 
factor (Gomez-Roman et al., 2003). It is indeed plausible that c-MYC’s role in regulating 
cell proliferation could at least in part be mediated through its effects on cell growth. 
G1–S progression of eukaryotic cells is controlled by the activities of the cyclin-
dependent kinase (CDK) complexes cyclin-D–CDK4 and cyclin-E–CDK2. c-Myc 
induces cyclin-E–CDK2 activity early in the G1 phase of the cell cycle, which is 
regarded as an essential event in MYC-induced G1–S progression (Berns et al., 1997). 
But how does c-Myc activate cyclin-E–CDK2? It was recently shown that CCND2 
(which encodes cyclin D2) and CDK4 are direct target genes of c-Myc (Bouchard et al., 
1999; Hermeking et al., 2000). Expression of CCND2 and CDK4 leads to sequestration of 
the CDK inhibitor KIP1 (also known as p27) in cyclin-D2–CDK4 complexes (Perez–
Roger et al., 1999). The subsequent degradation of KIP1 has been shown to involve two 
other c-Myc target genes, CUL1 and CKS (O’Hagan et al. 2000). By preventing the 
binding of KIP1 to cyclin-E–CDK2 complexes, c-Myc allows inhibitor-free cyclin-E–
CDK2 complexes to become accessible to phosphorylation by cyclin-activating kinase 
(CAK) (Perez–Roger et al., 1999). Increased CDK2 and CDK4 activities would result in 
Rb hyperphosphorylation and subsequent release of E2F from Rb. 
Recent studies support the idea that c-Myc may also exert important influences on the 
cell cycle by repressing genes, such as the CDK inhibitors P15 and P21—that are 
involved in cell cycle arrest, through the Myc– Max heterodimer interacting with 
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positively acting transcription factors such as Miz-1 and Sp1. The suppression of 
p21CIP1 expression by Myc is responsible for the failure of Myc-transformed cells to 
arrest in G1 phase after DNA damage. For instance, in the case of colorectal cancer, 
increased ß-catenin/TCF4 activity correlated with increased levels of c-Myc, leading to 
repression of p21 and ultimately to a proliferative phenotype of the cells. The interaction 
of Myc–Max with Miz-1 blocks the association of Miz-1 with its own co-activator (P300 
protein), with the subsequent down-regulation of P15 and P21 (Staller et al., 2001). 
Recent studies carried out in Drosophila (Moreno and Basler, 2004; de la Cova et al., 
2004) show that Myc has a role in the regulation of cell proliferation beyond its ability to 
induce transcription of growth-promoting genes. Cells with high levels of Myc 
expression can act as supercompetitors that are capable of both out-growing and inducing 
death in nearby cells with lower Myc levels. Although the mechanism of apoptotic 
induction is unclear, it involves the activation of genes that are known to trigger 
apoptosis in Drosophila cells, such as hid. Super-competition appears not to be a general 
property of a relative increase in growth rate, because the activation of other growth-
promoting pathways did not cause apoptosis in neighboring cells (de la Cova et al., 
2004). These observations, together with the wellestablished evidence that Myc plays a 
prominent role in the induction of growth-promoting gene expression, specifically the 
ribosomal protein genes, suggest a mechanism by which deregulated Myc expression can 
initiate tumor formation. Oncogenic mutations that lead to increased Myc expression 
(Nesbit et al., 1999; Salghetti et al., 1999) enable cells to increase their biosynthetic 
capacity and clonally expand faster than their wild-type neighbors, while simultaneously 
inducing cell death in those wild-type cells. This could allow cells with an 
inappropriately high level of Myc to become tumorigenic by rapidly overpopulating a 
tissue while readily acquiring secondary oncogenic lesions. 
. 
1.8 c-Myc and tumors 
In contrast to the tightly regulated c-myc gene in normal cells, which only express the 
gene when cells actively divide, cancer cells may express the gene in an uncontrolled 
fashion as the result of genetic aberrations. 
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Alteration of the c-myc gene, via retroviral transduction, retroviral insertion, gene 
amplification (Dalla-Favera et al., 1982), chromosomal translocation (Dalla-Favera et al., 
1982; Taub et al., 1982) and point mutation (Pasqualucci et al., 2001), represent one of 
the most common genetic lesions associated with cancer in multiple animal species and 
multiple tissues (Grandori et al., 2000). The common consequence of these alterations is 
the deregulated expression of the c-Myc protein in term of amount, time or cell context. 
Despite extensive studies and findings, fundamental questions regarding the role of Myc 
in tumorigenesis remain open. 
One of the most striking findings of the past years has been the discovery that the 
enhanced expression of Myc proteins contributes to almost every aspect of tumour cell 
biology (Pelengaris et al., 2002). Whereas the ability of Myc to drive unrestricted cell 
proliferation  and to inhibit cell differentiation had long been recognized, more recent 
work shows that deregulated expression of Myc can drive cell growth (Iritani and 
Eisenman, 
1999; Johnston et al., 1999) and vasculogenesis (Baudino et al., 2002), reduce cell 
adhesion (Frye et al., 2003), and promote metastasis (Pelengaris et al., 2002) and 
genomic instability (Felsher and Bishop,1999). Conversely, the loss of Myc proteins not 
only inhibits cell proliferation and cell growth (Mateyak et al., 1999; Trumpp et al., 
2001), but can also accelerate differentiation19, increase cell adhesion (Knoepfler et al., 
2002) and lead to an excessive response to DNA damage (Herold et al 2002). 
Recent results from several laboratories suggest that MYC inactivation in some cancers 
will not revoke tumorigenesis; rather, it will induce a transient loss of neoplastic 
character, marked by normal phenotype, that can be fully restored by Myc reactivation 
(Jain et al., 2002; Shachaf et al., 2004). The consequences of Myc inactivation and 
reactivation seem to depend upon the particular type of cancer. Myc inactivation in 
lymphoma commonly results in a permanent loss of a neoplastic phenotype. Thus, Myc-
induced skin and pancreatic islet cell tumours undergo regression upon Myc inactivation 
and that tumours reform quickly after Myc reactivation (ref). Similarly, Myc-induced 
breast cancer undergoes regression upon Myc inactivation that is fully revoked by Myc 
reactivation (Pelengaris et al., 2004). The precise target genes through which Myc 
functions in each of these pathways have remained elusive in some, but not all, cases. 
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 1.9 c-Myc and apoptosis 
Meanwhile several studies were discovering how Myc functioned as an oncogenic 
transcription factor Myc was discovered to actually trigger rapid apoptosis (Evan et al., 
1992), an endogenous and conserved program of cell suicide. Further, what rapidly 
became clear was that Myc was the rule, rather than the exception, as other oncogenes 
such as E1A (Lowe and Ruley, 1993) and E2F-1 (Kowalik et al., 1995) were then shown 
to behave in a similar fashion. This raised the hypothesis that apoptotic pathways must be 
disabled for oncogenes to promote transformation. 
Myc-induced apoptosis requires its DNA binding functions and dimerization with Max 
(Evan et al., 1992; Amati et al., 1993). Since so fare there are no identified mutants 
lacking the transactivation activity alone, it’s non easy to define which Myc function 
(transactivation or repression) is necessary for Myc role in apoptosis: likely both are 
important. 
Apoptosis is an important safeguard that protects the organism from tumour cells: an 
intrinsic response, an immune surveillance mechanism, that somehow senses things are 
amiss in the mutated cell and instructs its suicide, protecting the organism from being 
overcome by a few bad actors. At its most basic level, apoptosis is controlled by intrinsic 
survival pathways (Figure 4) that are necessary to block the cell death program, and 
those invoked by extrinsic signals that actively trigger the demise of the cell. Extrinsic 
apoptotic pathways are direct and efficient signals that provoke cell suicide, and are 
induced following ligation of the Fas/TNF-a family of death receptors with their ligands. 
Although is not clear yet at which level it occurs, Myc does sensitize some cell lines to 
TNF-a- and Fas-induced death (Hueber et al., 1997; Klefstrom et al., 1997), and in some 
T-cell hybridomas c-Myc is required for activation induced death, which in peripheral T 
cells is Fas dependent. There are evidences that Myc somehow blocks activation of NF-
kB by TNF-a (Klefstrom et al., 1997; You et al., 2002), which provides an essential 
survival function by regulating genes such as the antiapoptotic Bcl-2 family member bcl-
X. And in the Fas pathway Myc can target or components of the DISC, such as the RIP 
serine/threonine kinase (Klefstrom et al., 2002). MEFs and myeloid cells derived from lpr 
or gld mice, which have inactivating mutations in the Fas and Fas ligand genes,  
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respectively, are resistant to Myc-induced death (Hueber et al., 1997; Amanullah et al., 
2002). 
Another way Myc can induce apoptosis is through Bax. Bax is a proapoptotic bcl-2 
family member whose apoptotic function is antagonized by bcl-2 expression (Oltvai et 
al., 1993). Bax along with Bak inserts into mitochondrial membranes and forms channels 
for the release of cytochrome c. And Bax-deficient (but curiously not Bak-deficient) 
MEFs are remarkably resistant to Myc-induced apoptosis (Soucie et al., 2001; Juin et al., 
2002). 
 Is still controversial whether Myc directly activate Bax transcription, may be due to 
tissue or species specificity, but Myc is necessary (Soucie et al., 2001) and sufficient 
(Juin et al., 2002) for Bax activation. Myc can directly (human) or indirectly (mouse) 
induce the expression of Puma, leading to his association with the antiapoptotic proteins 
Bcl-2 and Bcl-XL, functionally sequestering these proteins and releasing Bax and Bak to 
continue the chain of destruction. Myc can also activate Bid  (another BH3 only factor 
Bcl2-family member) with consequent binding and activation of Bak bound to 
mitocondria (Wei et al., 2000), or repress the transcription of bcl-2 or bcl-X, but the way 
it occurs is still unresolved. 
Myc is able to induce apoptosis also activating the Arf-p53 pathway. Arf and p53 are 
both tumor suppressor protein. Mutation, deletion or silencing of the INK4a /ARF locus 
and p53 gene are the two most alterations in human cancer (Zambetti and Levine, 1993) 
and impairs Myc-induced apoptosis (Zindy et al., 1998). Myc activation in primary cells 
is associated with a profound induction of both Arf and p53 protein levels. This response 
occurs at several levels. First, in some cell types, p53 is a transcription target of Myc and 
indeed the gene harbors an E-box in its promoter-regulatory region (Reisman et al., 
1993). However, in most cells, p53 protein levels are more profoundly induced following 
Myc activation (Zindy et al., 1998), usually through the agency of Arf in blocking p53-
inhibitor Mdm2 functions, but perhaps also via effects of Myc on the Atm pathway 
(Lindstrom and Wiman, 2003). 
How Myc induces Arf remains unclear. Since de novo protein synthesis is required 
(Zindy et al., 1998), Myc likely cooperates with other transcription factors or signaling 
proteins that regulate Arf transcription. One of these can be E2f1, as Myc induces E2f1 
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expression in primary cells (Sears et al., 1997; Baudino et al., 2003; Fernandez et al., 
2003) and E2f1 has been suggested to induce Arf directly (Bates et al., 1998). Even if 
there are evidences that Myc can clearly activate Arf and p53 expression and kill cells in 
the absence of E2f1 (Baudino et al., 2003). Another candidate as a mediator of the Arf 
response to Myc is the calcium-regulated serine-threonine kinase DAP. DAP expression 
is augmented by Myc, the kinase is sufficient to activate Arf, and loss of DAP impairs 
Myc's ability to induce Arf and p53 and to trigger cell death (Raveh et al., 2001). 
Bmi-1, Twist, Tbx2 and Tbx3 are transcription factors that repress Arf transcription and 
block Myc-induced apoptosis (Jacobs et al., 1999a; Maestro et al., 1999; Brummelkamp 
et al., 2002; Lingbeek et al., 2002), but no effect of Myc on the expression and/or activity 
of these Arf repressors have never been properly evaluated.  
 
1.10 c-Myc and genomic instability 
There are evidences that link Myc to genomic instability. The term genomic instability 
refers to genetic changes that affect the normal organization and function of genes and 
chromosomes. These alterations may be structural (point mutations, deletions, 
translocations, inversions…) or numerical (that leads to changes in the number of 
chromosomes).Genomic instability has frequently been associated with malignant 
transformation of cells. However, it is also found in normal and (pre)malignant cells. For 
example, normal mammalian lymphocytes use a form of genomic instability during 
normal recombination of their immunoglobulin (Ig) and T-cell receptor genes. Moreover, 
gene amplification occurs normally as part of development-specific programs in other 
species as Xenopus, Drosophila and Tetrahymena (Stark, 1993). 
c-Myc/Max heterodimers are involved in the genomic instability of gene whose products 
are essential for DNA syntesis. Many, but not all, of these genes are also transcriptional 
targets of c-Myc/Max. For instance intrachromosomal as well extrachromosomal locus-
specific amplification of the dihydrofolaate reductase (DHFR) gene (Mai, 1994) occurs 
72 hours after c-myc upregualtion and following enhanced bindig of c-Myc/Max 
heterodimers to the DHFR 5’ flanking E-boxes. This was proven both in tissue culture 
and in mouse models. Furthermore c-Myc is associated to locus-specific genomic 
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instability of other genes as cyclin D2 (Mai et al., 1999), Ribonucleotide Reductase R2 
(Kuschak et al 1999) and CAD (Fukasawa et al., 1997). 
Inducible system, as the fusion protein Myc-estrogen receptor (Myc-ER) responsive to 
hydroxytamoxifen, revealed that continued Myc activation in vivo and in vitro leads to 
structural and numerical chromosome alterations (karyotypic instability) that directly 
contributes to the tumorigenic potential of the cells (Feisher and Bishop, 1999). c-Myc-
induced genomic instability is transient if c-Myc activation is induced only for a single 
time, as demonstrated in transgenic mice where malignant c-Myc induced T cell 
lymphomas, acute myeloid leukemias, hematopoietic tumors regressed when c-myc 
deregulation was removed. 
Open question is how c-Myc induces gene amplification.  A model proposed is the 
replication-driven amplification (or onion skin model) that postulates that re-replication 
of a particular gene occurs within the cell cycle, whereas usually each gene replicates 
only once in each cell division cycle (Hamlin JL and Ma C., 1990). The finding of 
several rounds of amplification of R2 within a single cell cycle as consequence of c-myc 
overespression (Kuschak et al 1999) supports the idea of a replication-driven model for 
c-Myc induced genome instability. 
 
A role for c-Myc in DNA replication was first reported by Classon et al. in 1987. The 
authors showed that lymphocytes with high level of c-Myc protein supported the 
replication of Simian Virus 40 (SV40) better than lymphocytes with lower level of the 
protein. Later it was demonstrated that c-Myc was the limiting factor for ionizing-
induced SV40 gene amplification in semi-permissive Chinese hamster embryo cells. 
Furthermore, it became evident that c-Myc was instrumental in the binding of protein 
complexes at the minimal origin of SV40 (Classon et al., 1993).  
Is c-Myc then a replication-licensing factor? 
 
1.11 MCM proteins and DNA replication 
DNA replication is a highly controlled and coordinated process required for maintenance 
of the genome, that must be duplicated precisely once per cell cycle. 
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Since the human genome is not one long continuous thread of DNA but is divided into 46 
chromosomes per diploid cell, each chromosome contains thousands of starting points of 
replication (origins of replication). The activity of these origins is coordinated as they fire 
in a defined temporal fashion during S phase. Different replication origins fire at different 
times during S phase, creating a ‘replication timing program’ whereby different segments 
of chromosomal DNA are replicated at distinct times. To avoid re-firing of the same 
origins eukaryotes have found a way to distinguish between replicated and unreplicated 
DNA (Rao and Johnson, 1970). Experiments in Xenopus laevis eggs suggest a model 
whereby replication origins were 'licensed' for replication during late mitosis and G1, but 
the license is removed as the DNA was replicated (Blow and Laskey, 1988). In the 
licensing of the origins, the Mcm complex plays a central role. Mcm2–7 proteins form an 
essential component of the pre-replicative complex (pre-RC) of proteins that are found at 
replication origins during G1 phase. Replication origins are licensed by stably binding 
complexes of the Mcm 2–7 proteins, and then they can initiate a pair of replication forks. 
Ones the DNA replication is started Mcm 2-7 proteins are displaced from the origins, 
probably traveling ahead of the replication fork (Blow and  Hodgson, 2002; Nishitani and 
Lygerou, 2004). In this way the license is never associated with replicated DNA. 
The MCM protein family was originally isolated from a genetic screen in budding yeasts 
which were defective in minichromosome maintenance, showing a high rate of loss of 
plasmids that contained a cloned centromere and replication origin (Sinha et al., 1986). It 
includes only the six proteins Mcm2 through Mcm7 that show sequence homology with 
hexameric DNA helicases and that share a region of sequence similarity called the MCM 
box that includes two ATPase consensus motifs (Koonin, 1993). The MCM family is 
conserved in all eukaryotes, but not in prokaryotes, even if MCM-related proteins exist in 
Archaea (Kearsey and Labib, 1998). Physical interactions were identified in vivo by 
using two-hybrid, co-immunoprecipitation, and biochemical purification (Adachi et al., 
1997) suggesting that the bulk of MCMs in vivo associate in a heterohexamer with 
1:1:1:1:1:1 stoichiometry, although there are likely to be small amounts of single MCMs 
and MCM subcomplexes in the cell. Since no mutants that disrupt complex assembly are 
viable (Lei et al., 2005), their assembly is necessary, however non sufficient, for their 
function (e.g. they require their NLS or ATPase domain). Chromatin 
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immunoprecipitation experiments have revealed that the MCM proteins are associated 
with replication forks as they elongate along chromosomal DNA (Aparicio et al., 1997), 
whereas inhibition of Mcm2–7 function during S phase causes a rapid cessation of DNA 
synthesis (Labib et al., 2000; Shechter et al., 2004), indicating that Mcm2–7 function is 
required for fork progression as well as initiation. These observations all indicate that 
Mcm2–7 functions as a helicase that unwinds DNA ahead of the replication fork. In vitro 
experiment already showed that the Mcm4,6,7 core will itself dimerize to form a 
dimertrimer (Mcm4,6,7)2 that is associated with DNA helicase activity (Ishimi et al., 
1996). Moreover the structure of the N-terminal region of the Methanobacterium 
thermoautotrophicum MCM protein (MtMCM) has been solved (Fletcher et al., 2003). 
This archaeal species has only one MCM protein, which assembles into two head-to-head 
homohexameric rings, that have helicase activity (Shechter et al., 2000), with a large 
positively charged channel running through the centre that is wide enough to surround 
double-stranded DNA (Figure 5). The C-terminal helicase domain that is missing from 
the crystal structure could form an extra ring facing away from the dimer interface. This 
conclusion is supported by electron microscopy of the full-length archaeal MCM protein, 
which shows a bilobed hexameric structure with a large central channel (Pape et al., 
2003). 
 
1.12 Prereplication Complex and licensing reaction 
Replication initiation depends on identification and activation of origins of replication 
distributed throughout the genome. The replication origin is marked by the binding of a 
complex of proteins called ORC (for “origin recognition complex”) (Bell, 2002). ORC 
recruits two further proteins, Cdc6 and Cdt1, which are required for the loading of 
Mcm2–7 in order to form the prereplication complex (pre-RC) and the functional 
licensing of the origin although the mechanism is poorly understood (Blow and  
Hodgson, 2002; Nishitani and Lygerou, 2004) (Figure 6). As the ring-shaped structure of 
MCM2-7 encircles the DNA, it suggests that ORC and Cdc6 might act as an ATP-
dependent clamp-loader. Among the pre-RC components in metazoans, Orc1, Orc4, and 
Cdc6 have both Walker A and Walker B motifs, whereas Orc5 has only a Walker A 
motif. The Walker A motif is critical for ATP binding and the Walker B motif is required  
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for ATP hydrolysis. Given that a nonhydrolyzable ATP analog inhibits the loading of 
MCM2-7, but not loading of ORC and Cdc6 (Harvey and Newport, 2003b), it seems 
likely that ATP hydrolysis is used to load MCM2-7 on chromatin. This model is 
consistent with the observation that ORC, Cdc6 and Cdt1 are only required for the 
loading of Mcm2–7 onto DNA (licensing), but are not required for the continued 
association of Mcm2–7 on DNA once this has occurred (Maiorano et al., 2000).Cdt1 
directly binds members of the Mcm2-7 complex, and this interaction is enhanced by 
Cdc6 that must already be bound to the chromatin before Cdt1 can join the complex in an 
active form (Cook et al., 2004; Tsuyama et al., 2005). 
Mcm2-7 complex show low helicase activity in vitro.  Consistent with this observation, 
binding of Mcm2-7 to the DNA is not enough to initiate replication, but it requires an 
activation step in witch critical seems to be the loading of Cdc45 (Pacek and Walter, 
2004). Cdc45 is required for both activation of MCM2-7 on origins and chromosome 
unwinding at the replication forks. 
The Mcm2-7 not only can be activated, but also derepressed at transition from G1 to S 
phase. Mcm7 interacts with a tumor suppressor protein, pRB  with consequent inhibition 
of DNA replication in a Xenopus in vitro DNA replication assay system. Active cyclin 
D1/CDK4 catalyzes the dissociation of a pRB-Mcm7 complex (Gladden and Diehl, 
2003). Thus, pRB may suppress MCM2-7 helicase activity until activation of Cdk in a 
manner similar to how it represses E2F-mediated transcription until S phase. 
 
1.13 MCM paradox 
MCM proteins are in vast excess compared to the number of fired origins (Edwards et al., 
2002). Although in Escherichia coli, two helicases per origin seem sufficient to allow 
bidirectional DNA replication, with each helicase acting at a single replication fork, in 
Eukaryotes 10-40 Mcm2-7 hexamers are present at each replication origin (Edwards et 
al., 2002).Furthermore most of Mcm2-7 are distributed all over the chromatin and don’t 
co-localize with replication forks or sites of DNA synthesis (Edwards et al., 2002; Lei et 
al., 1996). One possible explanation for this paradoxal distribution is that the Mcm2-7 
complex doesn’t function as typical DNA helicase but as a fixed pump that unwind the 
DNA in fixed replication forks during S phase (Laskey and Madine, 2003) (Figure 7). 
 30
  31
 Another possibility is that all those Mcm2-7 don’t work in DNA synthesis, but are 
loaded for contingency or other function. For instance one proposal is that Mcm7, 
interacting with ATRIP (a protein that activate the ATR kinase), is a critical regulator of 
S-phase check point (Cortez et al., 2004). It is also possible that the 10–40 Mcm2–7 
hexamers that are loaded onto each origin form a number of back-to-back dimers, each of 
them could provide a different site at which initiation could occur. This might provide 
redundant origins for use if various components of the replication machinery were to fail. 
 
1.14 Once and only once 
How does the cell control DNA replication to occur only once per cell cycle, avoiding 
extra-copies of chromosomes leading to genome instability and, as last consequence, to 
cancer? To prevent re-firing of replicated origins during the S phase, it is important that 
the ability to license new replication origins is downregulated before entry into S phase. 
Mcm2-7 remains inactive in G1 phase, due to the low activity of CDK. Once DNA 
replication is initiated following Mcm2-7 activation, no additional Mcm2-7 complexes 
are loaded onto origins as combinatory effect of CDK activity and functional inactivation 
of their loading factors.  
Orc1 (the ATPase subunit of ORC) in S phase is targeted of proteasomal degradation by 
SCF(Skp2) ubiquitination, probably due to Cdk2 activity. Excess of Cdc6 is exported out 
of the nucleus after Cdk2-mediated phosphorilation. Furthermore, phosphorylation of 
Mcm4 dramatically reduces its affinity for the chromatin in Xenopus extract and is 
associated to low level of DNA synthesis (Ishimi et al., 2003). 
But downregulation of Cdt1 activity is the main strategy adopted by metazoans in 
preventing licensing during S and G2 phase. Cdt1 overexpression in human, Drosophila 
and Xenopus leads to re-replication, enhanced by co-expressing Cdc6 (Maiorano et al., 
2005). The levels of Cdt1 are regulated during the cell cycle, being stable in G1 when pre-
RCs are formed and degraded in S phase when pre-RCs are fired and disassembled 
(Nishitani et al., 2001). Regulation is primarily at the protein level, as mRNA levels of 
Cdt1 remain constant throughout the cell cycle. Cdt1 is phosphorylated in vivo by Cdk2 
or Cdk4 and its phosphorylation is required for interaction with the F-box protein Skp2 
and proteasomal degradation (Liu et al., 2004). There is also another mechanism for Cdt1 
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degradation that is Skp2-indipendent, but triggered by replication and that is interestingly 
required for normal progression of S phase (Takeda et al., 2005). 
Another key regulator of Cdt1 activity is geminin. Geminin is destabilized during G1 
phase and accumulates during S, G2, and M phases of the cell cycle. At the metaphase-
to-anaphase transition, geminin is ubiquitinated by APC and degraded by the proteasome 
to allow pre-RC formation in G1 phase. Geminin binds to Cdt1 and inhibits Cdt1 binding 
to both DNA and to Cdc6 and MCM2-7 subunits (Cook et al., 2004). But geminin also 
stabilizes Cdt1 during G2 and M phase, as RNAi experiment demonstrated in mammalian 
cells (Ballabeni et al., 2004). This stabilization seems to be important because the 
decrease in Cdt1 protein levels at mitotic exit cannot be recovered later by de novo 
protein synthesis. For this reason, the geminin-dependent accumulation of Cdt1 during 
mitosis is essential for pre-RC formation and DNA synthesis in the following cell cycle. 
Like geminin, also Cdks seem to have a positive role in pre-RC formation, as 
experiments show Cdk2 to phosphorylate Cdc6 preventing it from poliubiquitination by 
APC. This stabilization is critical when cells enter the cell cycle from a quiescent state 
(Mailand and Diffley, 2005). 
What happens if re-replication occurs? Structural problems that take place after origins 
re-firing, as stalled forks or DNA damage, rather than re-licensing itself, trigger 
checkpoint kinases ATM/ATR activation. These proteins in turn activate many 
downstream kinases as Chk1 and Chk2. ATM/ATR pathways inhibit Cdk2 and Cdc7 
activity respectively. Cdc7 is required for initiation of DNA replication. In combination 
with Cdk2 protein kinase, Cdc7 promotes binding of Cdc45 to the pre-RC (Jares and 
Blow, 2000). In this way ATM/ATR prevent origin firing by inhibiting loading of Cdc45 
on the chromatin in presence of DNA damage (Costanzo et al., 2000, 2003). Also 
subunits of Mcm2-7 are directly phsphorilated by ATM/ATR after DNA damage (Cortez 
et al., 2004; Yoo et al., 2004), but the meaning of this modification is still not well 
known. 
Overexpression of Cdt1 or Cdc6, and consequent re-replication, leads to p53 activation 
and apoptosis in addition to cell cycle arrest (Vaziri et al., 2003). Instead downstream 
effector of geminin depletion is checkpoint kinase Chk1 that leads to G2 arrest, and 
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ultimately, in case this block is over-ridden, to p53-indipendent apoptosis (Zhu et al., 
2004).  
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CHAPTER II 
Aim and Results 
 
Aim 
Although a number of proteins binding c-Myc have been identified, their physiologic role 
remains unclear. The aim of this work is to isolate the protein complex containing c-Myc, 
to identify its components and to determine the contribution of selected ones on the c-
Myc influence on the cell biology. 
 
Results 
2.1 Complex purification 
To isolate the c-Myc containing protein complex from cell, we used an epitope-tagging 
strategy that was already successfully adopted in the lab. We used a human lung 
carcinoma H1299-derived cell line (H/HF2), which stably express low-level of a 
hemagglutinin (HA)/ Flag double tagged form of c-Myc. This cell line was already 
available in the lab. c-Myc is a very unstable protein, with an half-life of 30 minutes, that 
is ubiquitinated and degraded by he proteasome pathway (Salghetti et al., 1999). The 
MG132 proteasome inhibitor was added directly to the cell cultures before harvest in 
order to increase the overall c-Myc level by inhibiting the degradation pathway. To 
isolate complex containing the epitope-tagged protein, nuclear extracts from the cell line 
and from native cells as control were processed by affinity chromatography in batch. The 
co-purified proteins were separated by SDS-PAGE and stained by Blue Comassie 
(Figure 8). Comparing the protein pattern between the c-Myc stable cell line and the 
parental H1299 cell line, specific bands were cut from the gel and analyzed by 
microsequencing by mass spectrometry (MALDI-TOF and MS-MS). The recorded mass 
signals were used for protein database search. Among the protein identified in the c-Myc 
associated complex, Mcm7 and Mcm5 were found as novel c-Myc protein partners. 
Minichromosome Maintenance (MCM) proteins were originally identified in yeast 
(Maine et al., 1984) and are conserved in all eukaryotes. They are proposed to be the 
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DNA helicase and play a key role in DNA replication (see introduction).  Those two 
proteins catalyzed our interest since recently the MCM proteins are becoming a 
diagnostic and prognostic marker for many tumor (breast, lung, brain, prostate, bladder 
etc.) (for review: Tachibana et al., 2004) substituting the more conventional proliferation 
marker as Ki67 and PCNA.  
 
2.2 c-Myc interacts with the Mcm7 
In order to validate the interaction between c-Myc and the new protein, Mcm7 cDNA 
was cloned in a eukaryotic vector expressing the protein as HA tagged. The Mcm7 cDNA 
was amplified by PCR from a Ramos cDNA library. 293T cell line were co-transfected 
with plasmid expressing c-Myc, Max and Mcm7-HA. The total cell lysates were 
immunoprecipitated with specific antibodies recognizing c-Myc or Max and tested for 
Mcm7 co-immunoprecipitation by western blot using an HA antibody. Mcm7 was 
detected in both c-Myc and Max immunorpecipitations, but not when irrelevant IgG were 
used as control for co-immunoprecipitation specificity (Figure 9). The different amount 
of Mcm7 that co-immunoprecipitates with Max directly correlates with the level of c-
Myc (lanes 2, 4 of IP), suggesting that Max interaction with Mcm7 is c-Myc mediated. 
To verify that this interaction was physiologic and not due to c-Myc overexpression or 
tagging, the interaction between the endogenous proteins was tested in native cell. 
 Protein extracts from different cell lines were separated by SDS-PAGE tested by 
Western Blot with specific antibodies for the expression of c-Myc and Mcm7 (Figure 10 
A,B). Three different cell lines where chosen: MCF7 and Raji, expressing low and high 
level of c-Myc respectively, and the parental cell line H1299. Endogenous c-Myc and 
Max were immunoprecipitated from nuclear extract with specific antibodies. Mcm7 co-
immunoprecipitated with c-Myc and Max in all the cell lines tested, but non when 
irrelevant IgG as control antibody (from the same species of Myc-Max antibodies) were 
used. This confirmed that Mcm7/c-Myc interaction was real. 
 
2.3 c-Myc interacts with all the components of the MCM helicase 
Since Mcm7 belongs to a complex of six proteins (Mcm2-7), and among them Mcm5 
already co-purifies with c-Myc complex, we sought to determine whether c-Myc interacts  
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with the other components of the MCM complex. The cDNA of the other MCM proteins 
(2, 3, 4, 5 and 6) was cloned in vector expressing them as HA-tagged proteins. As for 
Mcm7, the interaction was tested in 293T cells by co-transfection and co-
immunoprecipitation. A possible cooperative role of Mcm7 (the protein originally 
identified in the cMyc complex) was also tested. Figure 11-13 show that all the MCM 
proteins co-immunoprecipitate with c-Myc independently from the presence of Mcm7. 
Again, the recruitment of the MCM proteins to the heterodimer c-Myc/Max is Myc 
dependent, as suggested by the direct correlation between the level of MCMs and of c-
Myc, coming down along with Max. The interaction is specific since no detectable 
binding of the HA-tagged proteins is present in the control lanes.  
Next we sought to confirm this interaction between c-Myc and the endogenous MCMs. 
The c-Myc complex from the stable cell line expressing a tagged form of c-Myc 
previously purified was separated by SDS-PAGE. The presence of all the endogenous 
proteins was verified by Western Blot using specific antibody (Figure 14 A). All the 
MCM proteins were found co-immunoprocipitated along with c-Myc.  
Furthermore, we wanted to validate these interactions in absence of proteasome inhibitor. 
Nuclear extract from H1299 cell line was immunoprecipitated with c-Myc specific 
antibody or aspecific IgG as control. Western blot following SDS-PAGE separation of 
the samples revealed the effective co-immunoprecipitation at list of some of the MCM 
proteins (Figure 14 B). Not all the MCMs were detectable, likely due to the sensibility of 
the antibodies. 
These data confirm that c-Myc interacts with all the MCM proteins and suggest that these 
interactions are physiologic. 
 
2.4 Direct interaction between Myc and the MCM proteins 
In order to test whether c-Myc interacts directly or not with some or all the component of 
this complex, the cDNAs of the MCMs were subcloned in a vector expressing them in 
bacteria as proteins tagged with six histidins (His6) at the N-terminus and HA at the C-
terminus. In the lab was already available a prokaryotic expression vector for a double 
tagged c-Myc protein (HA-Myc-Flag). The recombinant protein were expressed in 
bacteria (E coli) and purified from cell lysates using a double-tag sequential purification  
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in order to obtain full length products and no cleaved or degraded forms. The 
recombinant proteins were analyzed on SDS-PAGE for purity and quantitated by 
Comassie staining using a bovine serum albumin (BSA) curve as standard. In vitro pull 
down experiments were first performed incubating the recombinant c-Myc with Mcm7. 
After Myc immunoprecipitation with M2 Flag antibody the protein were separated by 
SDS-PAGE and the co-immunoprecipitation of Mcm7 was revealed by western blot. Max 
was used as control for the pull down (Figure 15 A). Next all the other MCMs were 
separately incubated in presence of or absence of Myc and a direct interaction between 
the two proteins tested was observed (Figure 15 B,C). 
The in vitro pull down experiments suggest a direct interaction of c-Myc with all the 
MCM proteins. 
 
2.5 Mapping the interaction between c-Myc and MCM complex 
We were then interested in to identify the protein domains that were involved in these 
interactions. In order to map the region within Mcm7 that binds directly to c-Myc, we 
employed different truncated mutants containing various domains of Mcm7 molecule 
generated by PCR amplification and cloned in bacterial GST expressing vectors. Each 
protein after bacterial purification was subjected to SDS-PAGE followed by Comassie 
staining. The proteins, so quantitated, were incubated separately with equal amount of 
HA-Myc-Flag. After incubation with glutation-sepharose beads, the samples were 
analyzed with antibody directed against the HA tag or the GST. The experiment revealed 
that the C-terminal region of Mcm7 binds c-Myc. Surprisingly, interaction between the 
GST-full length Mcm7 and HA-Myc-Flag was not detectable, probably due to problem in 
the folding of the GST-fusion protein in a bacterial environment (Figure 16). Then we 
adopted the same strategy to map the c-Myc binding region on Mcm7 and Mcm2.  A 
panel of truncated mutants of c-Myc fused to GST was generated by PCR amplification 
and the recombinant proteins purified from bacteria were incubated in presence of His6-
Mcm7-HA first, and His6-Mcm2-HA later. As reported in Figure 17 we identified two 
regions of c-Myc directly interacting with Mcm7: one N-terminal encompassing the 
MycboxII, and another C-terminal including the HLH/LZ domain. Only the C-terminal 
domain of c-Myc is involved in the binding of Mcm2 (Figure 18). We also tested  
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whether Max is able to directly interact with Mcm7, but consistently with the data from 
the in vivo interaction, no binding was found (Figure 19). 
To confirm the mapping in vivo we generated a set of vectors expressing truncated 
portions of full length c-Myc protein tagged with HA. These constructs were co-
transfected in 293T cells with a vector expressing the Mcm7 full length no tagged. The 
cell lysates were analyzed by immunoprecipitation using an antibody against HA (for c-
Myc fragments) followed by western blot with an antibody specific for Mcm7. The result 
showed in Figure 20 suggests that c-Myc binding site is restricted to an N-terminal 
region including the mycboxII. Further mapping to validate this data with a different set 
of c-Myc mutants showed that deleting just that region is not sufficient to impair the 
binding to Mcm7, but a bigger N-terminal portion was needed to be deleted (Figure 21). 
Not conclusive was also our attempt to better characterize the interaction between c-Myc 
and Mcm2. The panel of truncated mutants of c-Myc was co-transfected in 293T cells 
with a vector expressing the Mcm2 full length no tagged. Mcm2 co-immunoprecipitated 
with an internally inconsistent pattern of c-Myc mutants (Figure 22). 
As reverse strategy we generated truncated mutants of Mcm7 tagged with HA according 
to the scheme adopted for the in vitro mapping, and examined their interaction with full 
length c-Myc. Despite the clear result obtained in vitro, we could not identify a specific 
region of Mcm7 that binds c-Myc since all the mutants co-immunoprecipitated with c-
Myc, as reported in two complementary experiments in Figures 23. 
 
2.6 c-Myc poorly co-localizes with Mcm7 
To better characterize the interaction between c-Myc and Mcm7, we investigated whether 
the two proteins were associated in the same sub cellular compartment. Since both the 
proteins are nuclear, we checked if they co-localize on the chromatin. Considering that c-
Myc is degraded in S phase (Lehr et al., 2002) and Mcm7 is released from chromatin 
after S phase, H1299 cells were synchronized in G1/S transition with a double 
thymidine/mimosine block. Due to the considerable nucleoplasmic pool of Mcm7, in 
order to avoid a diffuse staining for this protein, after fixing the cells the nuclei were 
permeabilyzed with triton. The treatment releases the entire nucleoplasmic protein 
fraction. The chromatin-bound fraction was hybridized with specific antibody against  
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c-Myc and Mcm7. Analysis with a confocal microscope revealed that the level of co-
localization of the two proteins is very low, roughly 15% of the spots co-localized 
(Figure 24).  
 
2.7 c-Myc associates with the MCM complex along the cell cycle 
To further characterize the association between c-Myc and the MCMs we wanted to 
study this interaction along the cell cycle. H1299 cells were synchronized in G1/S by a 
double thymidin/mimosine block. After the block was released in fresh medium, the cells 
were harvested at different time points. The cell cycle profile of each sample was 
determined by FACS analysis. c-Myc was immunoprecipitated from cell lysates using a 
specific antibody. The complex of proteins co-immunoprecipitated with c-Myc was 
analized by western blot. Using a specific antibody against Mcm7 we found that the 
association between the two proteins is stable all along the cell cycle (Fugure 25). 
 
2.8 Synchronous recruitment on the chromatin 
The MCM complex is thought to be the DNA helicase that unwinds the double helix 
allowing the DNA polymerase to bind one strand of the DNA and to move along it during 
the replication. The MCMs binding on chromatin is tightly regulated: they are recruited 
during G1 and are released after S phase. c-Myc is also a protein that binds the DNA, but 
up to date there are non clear study about its cycle regulation on chromatin. We wanted to 
verify whether there is any temporal correlation during the cell cycle between the loading 
on the chromatin of c-Myc and of the MCMs. H1299 cells were synchronized in mitosis 
with a thymidine-nocodazole block. After “shake off” the floating mitotic cells were 
collected and re-plated. Cells were harvested at different time and chromatin fractionation 
was obtained lysing the samples in CSK buffer (10mM HEPES-Na pH 7.9; 100mM 
NaCl; 1.5 mM MgCl2; 300 mM Sucrose; 50 mM NaF; 0.1 mM Na3VO4; Proteinase 
inhibitor) (Mendez & Stillman, Mol Cell Biol 2000). Western blot analysis with antibody 
against Myc, Mcm2 and Mcm7 confirmed that the loading of the MCMs occurs during 
late mitosis/G1, and showed that c-Myc, although detectable already during the mitosis, 
has a boost of loading on the chromatin starting from the end of mitosis and during the 
G1. An antibody specific against Max revealed that the protein behaves like c-Myc  
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although its level on chromatin after the end of mitosis is more stable compared to the c-
Myc one. The same western blot performed on the Triton-soluble fraction reveal that the 
cytoplasmic-nucleoplasmic level of the three proteins is stable during the mitosis-G1. 
Blotting for phospho-histone H3, a marker for the mitosis, revealed the effective block in 
M phase, and the synchronous re-entry the cell cycle of the cell populations (Figure 26). 
 
2.9 Sizing the complex 
After we demonstrated c-Myc interacting with all the components of the MCM complex, 
we sought to further characterize the interaction between these proteins in order to 
determine whether these interactions are individual and mutually exclusive, or 
alternatively, if c-Myc interacts with the entire MCM complex. The c-Myc interacting 
complex was freshly purified from the H/HF2 stable cell line and separated according to 
the size by a gel filtration chromatography in physiological conditions. The collected 
fractions were analyzed by SDS-PAGE and western blot using antibody against c-Myc, 
Max and Mcm7. The corresponding size of the fractions was determined by comparisons 
with molecular marker run in the same conditions. c-Myc was found widely distributed 
along the fractions, with a pick in fraction corresponding to molecular weight around 
400kD, and another one at higher molecular weight. Max distribution coincided with the 
first pick of c-Myc, but was not found in the higher molecular weight fractions. 
Unfortunately we failed in detecting any Mcm proteins (Figure 27). Since the presence 
of the proteins in the c-Myc complex was confirmed by western blot (data not shown), 
we thought that the no detectable level of the Mcm proteins was due to technical problem 
that occurred in the fractionation, as proteins adsorption by the resin of the column. To 
avoid any possible effect due to the column, the complex of proteins associated with c-
Myc was separated by ultracentrifugation in glycerol gradient. A protein marker was run 
along with the sample and the distribution of the known proteins was checked separating 
the collected fractions by SDS-PAGE and following blue comassie staining. Western blot 
analysis of the fractions confirmed the wide distribution of c-Myc along the gradient, 
mostly in two picks. More importantly we were able to detect Mcm7 and Mcm3 
distribution in high molecular weight fractions. Comparing with the molecular marker, 
the corresponding size of the complexes in which c-Myc and Mcm3/7 were found  
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associated exceed the molecular weight of a possible complex consisting in c-Myc, Max 
and the MCMs. The MCMs, at least in the initial steps of DNA replication, are recruited 
on the DNA by association with other proteins in a bigger complex, the pre-RC. 
Therefore we checked whether other members of the pre-RC complex were separated, by 
glycerol gradient, in the same fractions with c-Myc, Mcm3 and Mcm7. Western blot with 
specific antibody against Cdt1 and Cdc6, detected the presence of these two proteins in 
high molecular weight fractions, suggesting that c-Myc is associated in high molecular 
weight complex with different elements of the pre-RC (Figure28).  
 
2.10 No transcriptional implication in c-Myc-MCMs interaction 
c-Myc has been extensively studied for its role in regulating the transcription of its target 
genes. Although further validations are needed, weakly activated, or even repressed, the 
list of c-Myc target gene includes around 15% of the genome. Consistently with the 
emerging idea of an interaction between transcription and replication apparatus (for 
review Murakami and Ito, 1999) the MCMs have been implicated in several aspects of 
transcriptional control (Holland et al., 2002; Zhang et al., 1998Fitch et al., 2003). We 
were interested in verify whether the interaction between c-Myc and the MCMs was 
functional in c-Myc transcriptional activity. More specifically, we tested the influence of 
Mcm7 on the c-Myc mediated activation of a lucifarase gene under the control of tert 
promoter (as previously described in Wu KJ et al., 1999). 293T were transiently co-
transfected with the reporter gene, fixed amount of a vector expressing c-Myc and 
increasing amount of a vector expressing Mcm7 full length. Measurement of the 
luciferase activity showed that Mcm7 doesn’t positively affect the c-Myc activation of 
tert promoter. Instead a slight repression is relievable when high dose of Mcm7 are 
transfected. Western blot analysis confirmed the expression level of the proteins (Figure 
29) 
 
2.11 Mcm7 displaces c-Myc-Max from the E-box 
In order to assess whether the effect of Mcm7 on c-Myc-mediated transcriptional 
activation was a consequence of an impaired capability of the heterodimer c-Myc/Max to 
bind the DNA, we performed an oligonunleotide pull down assay. Vectors expressing  
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c-Myc, Max and Mcm7 were co-transfected in 293T cell in different combinations. 
Protein extracts were incubated with 38bp double strand biotinylated oligonucleotide 
encompassing the BN51-intron1 E-box previously described by Amati e co-workers 
(Greasley et al., 2000). The oligos were pulled down with streptavidin-conjugated 
agarose beads and the proteins interacting with the DNA were released from the binding 
boiling directly the samples in the SDS loading buffer. Western blot analysis showed that 
while Max can bind E-box in absence of c-Myc, c-Myc requires heterodimerization with 
Max to bind the consensus sequence, as it was already demonstrated. C-Myc binding to 
the E-box is impaired in presence of Mcm7. This happened even when a mutant of Mcm7 
lacking the C-term domain, that in vitro data show to be the region involved in the direct 
binding with c-Myc, was used (Figure 30). As control for aspecific interaction with the 
probe we designed another couple of oligonucleotides carry a mutation in the E-box 
(CACGTG to TACGTG). As expected the mutated E-box is not efficiently bound by c-
Myc/Max heterodimer. 
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CHAPTER III 
Discussion 
 
 
3.1 Complex purification 
The link between c-Myc and cancer was immediately clear since in 1982 its gene was 
discovered as the human homolog of retroviral gene responsible for the avian 
myelocytomatosis (Crews et al., 1982; Dalla-Favera et al., 1982). Deregulation of gene 
expression due to translocations, amplifications, or enhanced translation or protein 
stability has been found involved in nearly all types of tumor (Sears et al., 1999; Stoneley 
et al., 2000; Noguchi et al., 2001; Alarcon-Vargas et al., 2002; Channavajhala and Seldin, 
2002; Popescu and Zimonjic, 2002; Ruggero and Pandolfi, 2003; Tonini and Romani, 
2003). Enforced c-Myc expression is sufficient to provoke the entry and continuous, 
mitogen-independent, proliferation of cells (Cavalieri and Goldfarb, 1987, 1988; Eilers, 
1991), and it effectively blocks terminal cell differentiation (Coppola and Cole, 1986; 
Maruyama et al., 1987; Freytag, 1988). On the other side, c-Myc triggers rapid apoptosis 
in the cells (Askew et al., 1991; Evan et al., 1992). At the beginning c-Myc was thought 
to be a transcriptional activator. Interacting with Max, it recruits multiple co-activator and 
protein complexes to the promoter like Mediator complex, P-TEFb, TIP48/49, P300, 
GCN5 and others. But after the first empirically identified target genes, use of 
microarrays and a genome-wide survey has found that the number of gene that are bound 
by c-Myc and that are its potential target for regulation, is incredibly high (~15% of the 
genome )for any transcriptional factor so far studied. Moreover c-Myc not only activates, 
but also represses transcription of some target genes. After almost a quarter of century 
since its discovery, extensively studied, parsley-c-Myc exerts its influence in almost 
every aspect of cell biology, but the precise mechanisms how it does it, are still not well 
understood. In order to shed new light on its role in the cell fate, or to open new 
unexpected possibility to prevent Myc-mediated cancer insurgence, we wanted to identify 
proteins that interact with c-Myc under physiologic conditions. Previous studied have 
described several c-Myc interacting proteins that were isolated using ether strategies 
based on an in vitro formation of c-Myc containing complexes (MacMahon et al., 1998; 
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Wood et al., 2000), or two hybrid strategies that involved the formation of a non-
physiologic complexes. In addition these studies typically used deletion mutants of the c-
Myc protein, further allowing for the formation of non-physiological complexes. 
Although in each case the interaction with c-Myc was confirmed in vivo by co-
immunoprecipitation analysis, it is conceivable that these approaches have missed a 
number of proteins that are present in physiologic-formed c-Myc complexes. Based on 
these observations we decided to isolate the in vivo-formed complexes directly from cells 
using as a bait physiological level of a tagged full-length c-Myc protein. c-Myc is a low 
abundant protein, whose level is strictly regulated. In order to increase the intracellular 
level of the protein we used MG132, an inhibitor of the proteasome. Using this strategy, 
and high salt condition to increase the stringency of protein-protein interactions, we 
isolated several proteins that were not before described as associated to c-Myc. 
Intriguingly we have no evidence that among the protein co-immunoprecipitated in our 
experiment, there are also other known partners of c-Myc as TRAAP or TIP48/49. The 
presence, at least for TRAAP, was discarded by western blot analysis (data not shown). It 
is conceivable that the presence of MG132 is somehow selecting for some complexes in 
which c-Myc is associated rather than others, but the purified c-Myc protein was mainly 
non-ubiquitinated, as assessed by its migration on SDS-PAGE, by Western Blot with 
specific anti-ubiquitin antibodies, and mass spectrometry microsequencing (data not 
shown). So our complexes of proteins was not co-purified with a modified form of c-Myc. 
Moreover the interactions between c-Myc and the proteins identified were confirmed in 
native conditions and without MG132 treatment. 
Among the proteins that were identified by mass-spectrometry analysis we focused our 
attention to Mcm7, Mcm5. These two proteins belong to a complex of six proteins 
(Mcm2-7) that were originally isolated from a screening in yeast for mutants defective in 
minichromosome maintenance (Maine et al., 1984). Member of the MCM family have 
been found in all the eukaryotic by genetic and biochemical methods. It has been 
demonstrated that the MCM play a key role in DNA replication. Loading of the MCM on 
the origin is a critical step in order to start replication. According to sequence homology, 
in vitro data and crystal structure, they are thought to be the helicase that unwind the 
double strand of DNA (Ishimi, 1997; Fletcher et al., 2003). MCMs are expressed in 
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abundance in all phases of the cell cycle but they are degraded in cell that have exited the 
cell cycle, such as quiescent, senescent or differentiated cells (Madine et al 2000). This 
has recently led to their potential clinical application as marker for cancer screening as 
good alternative to the conventional KI-67 and PCNA (less effective and specific for 
proliferation). Given the involvement of c-Myc in tumorigenesis, we wondered whether 
the suggested interaction between c-Myc and Mcm7 could be functional in this process. 
Mcm7 has already been demonstrated to interact with Rb, and this interaction inhibits 
DNA replication in a Xenopus system (Sterner et al., 1998). Our finding would allow a 
scenario in which a tumour repressor and oncogene compete for binding the same protein 
with important consequences on DNA replication and then on the cell fate (normal cell 
vs. tumour cell). Moreover the MCMs are a distinct subgroup of AAA ATPase proteins. 
c-Myc has already been demonstrated to interact with two proteins with ATPase activity: 
TIP48 and TIP49, that are essential cofactors for c-Myc mediated transformation (Wood 
et al., 2000). These two proteins associate with each other as a double hexamer and are 
necassary for the catalytic activity of Ino80 complex involved in chromatin remodeling 
(Jonsson et al., 2004) with specific helicase and transcriptional activity (Shen et al., 
2000). Taken together these observations suggesting relevant analogies between these 
proteins and the MCMs, we thought it could have been worthy to study the interaction 
between c-Myc and the Mcm7 protein identified in our complex. 
 
3.2 Difficult mapping of the interaction between c-Myc and MCMs 
We validated the interaction between c-Myc and Mcm7, and demonstrated that c-Myc 
actually interacts with the entire MCM complex. We found that the interaction is direct 
with each component of the MCMs. 
It is not intuitive to imagine a model in which a single molecule of c-Myc interacts at the 
same time with the six subunits of the complex. A help comes from the analysis of the 
sequence of the MCMs. It has been suggested that the C-terminal region of MCM 
proteins may have a conserved helical structure. And it is known that domains containing 
α-helices are protein-protein interaction surfaces for contacting other proteins. Consistent 
with this structural data, the in vitro data show that the recombinant Mcm7 protein tested 
interacts with c-Myc through its C-terminal domain. The ability of c-Myc to interact with 
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all the MCM proteins could be essential to dynamically preserve the interaction between 
c-Myc and the MCM complex even in the presence of steric impairments due to other 
proteins binding the complex.  
Considering the high abundance of the MCMs, the small fraction of them interacting with 
c-Myc (<1%) and assuming the capability of c-Myc of interacting with all the MCMs, we 
can also explain the impossibility to define in experiment of in vivo mapping the binding 
region of Mcm7 on c-Myc. 
We do not exclude the possibility that c-Myc may have preferential partners among the 
MCMs in physiologic conditions, may be due to the ring shape conformation of the 
complex. This hypothesis is supported by the finding that in the complex of proteins 
isolated with c-Myc, all the Mcm proteins are not equally represented. As shown in 
Figure 14 Mcm3 and Mcm7, among the other subunits, have the relatively higher affinity 
for c-Myc. It is reported that the MCMs have a different affinity for one another forming 
different sub-complex, among them Mcm4/6/7 with helicase activity in vitro and 
Mcm2/3/5 with regulatory activity (Ishimi, 1997; Ishimi et al., 1998; Lei, 1996). Data 
from the crystal structure show that c-Myc/Max form antiparallel tetramers (Nair and 
Burley, 2003). This would allowed a model in which in the cell a tetramer c-Myc/Max 
can interact with a MCM complex through preferential direct binding with Mcm3 and 
Mcm7, moving to others member of the complex in order to face conformational changes 
of the ring following interactions with other putative partners. 
Unfortunately we failed in finding a point mutant of c-Myc that doesn’t interact with the 
MCM complex. The in vivo mapping of the interaction between c-Myc and Mcm2 and 
Mcm7 was never conclusive, possibly due to the same reason discussed above. Given the 
data from the in vitro-in vivo interactions showing binding between c-Myc and all the 
subunits of the complex, and the sequence homology among them, we expected the same 
result from the mapping with the other MCMs.  Even more troublesome was the 
dependence on the MycboxII domain of c-Myc for interaction with the MCMs that put a 
severe limitation in finding a mutant that exclusively impairs a specific Myc function 
without affecting all the others associated to its transcriptional activation domain (TAD). 
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3.3 Implication in transcription 
The MCMs have been implicated in several aspect of transcriptional control. Several 
MCM proteins have been shown to associate with the carboxy-terminal domain (CTD) of 
RNA polymerase II (Yankulov et al., 1999). The CTD is essential for transcription 
initiation and elongation in the context of chromatin (Sims et al., 2004). Evidences 
suggest that the MCM proteins associate with specific transcription factors. Mcm3-Mcm5 
heterodimer associates with a transcription factor stimulated by gamma interferon, 
STAT1α, for transcriptional activation (DaFonseca et al., 2001). In yeast Mcm7 regulates 
the transcription activity of Mcm1 by promoting Mcm1 binding to and activating its 
targets in vitro (Fitch et al., 2003).Well documented is the transcriptional activity of the 
heterodimer c-Myc/Max that is carried out recruiting to the E-box multiple co-activator 
and protein complexes. Among them there is Gcn5, a HAT. These observations 
suggested as functional meaning of the interaction between c-Myc and the MCMs, 
possible role in c-Myc-mediated transcriptional activation. Our results seem to discard 
this hypothesis. Not only Mcm7 failed in enhancing the transcriptional activation of tert 
promoter mediated by c-Myc, buy also seem to determine a slight reduction. More than 
possible involvements in c-Myc mediated transcriptional repression, a promoter 
specificity effect in determine the outcome of this experiment should be considered. In 
the specific context of the tert promoter is possible that Mcm7 can compete with the 
physiologic co-activators for the binding with c-Myc. Other possible explanation of this 
result comes from another experiment that shows the impairment of the c-Myc/Max 
heterodimer in binding the E-box determined by Mcm7. This data can be considered 
consistent with the one deriving from the ChIP studies of c-Myc genome binding. 
Fernandez et al. reported that in physiologic conditions endogenous c-Myc normally 
binds 7% of non E-box promoters. This number would rise up to 88% in case of ectopic 
expression of c-Myc (Fernandez et al., 2003). Together with the finding that there is a 
lean correlation between binding and transcription among the c-Myc bound genes (Zeller 
et al., 2003). These observations lead us to consider alternative functional meaning for 
the interaction c-Myc/MCM complex other than transcription.  
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3.4 Implication in replication 
It is well characterized that MCMs play an important role in replication. There are also 
compelling evidences that link c-Myc to replication. One of the key biological functions 
of c-Myc is to promote G0 to G1 and G1 to S transition (Eilers, 1999). And 
overexpression of the d-Myc in Drosophila has been shown to shorten the G1/S 
transition. It also allows the replication of SV40 in human lymphoma cells (Classon et 
al., 1987) and in vitro replication system, using HL-60 cells nuclear extract, is blocked by 
addition of anti-c-Myc antibody (Iguchi-Ariga et al., 1987). Furthermore overexpressed 
c-myc was shown to be able to uncouple DNA replication from mitosis in rodent and 
human cells (Li and Dang, 1999), and to promote locus-specific amplification of a 
number of target genes (DHFR, Cyclin D2, Ribonucleotide Reductase R2) (Mai and 
Mushinski, 2003). But a clear proof that links c-Myc to replication control, explaining the 
mechanism, is still missing. 
It is therefore intuitive to imagine the MCMs as possible link between c-Myc and control 
of DNA replication. This could represent a new function for a protein, c-Myc, that 
already exerts its influence at several levels in the cell biology, including interaction with 
new partners, new regulatory pathways. On the other hand we cannot exclude the 
possibility that this is a new outcome of the well characterized c-Myc transcriptional 
activity. Some evidences support this second hypothesis. Mcm2 has been demonstrated to 
interact biochemically and genetically with MYST family protein Hbo1 whose associated 
histone acetyltransferase (HAT) activity has been suggested to play a direct role in the 
process of DNA replication (Burke et al., 2001). c-Myc also recruits for its function as a 
transcriptional activation some histone acetyltransferases as GCN5 and TIP60. It is 
conceivable imagine that c-Myc and MCMs synergistic interact to bring their respective 
partner (HAT) on the chromatin inducing that structural remodeling in the double helix 
that allows the replication and/or transcription apparatus to seat on the DNA. This model 
would be consistent with the emerging opinion about transcription and replication as 
tightly interconnected (Murakami and Ito 1999). 
More than an indirect role, a direct involvement of c-Myc in controlling replication is 
supported by our work. Here we have demonstrated that c-Myc interacts with a complex 
that is directly involved in DNA replication. Loading of MCMs on the origin is necessary 
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step for origin to fire. During S phase, when the forks start, different mechanisms by 
which cells avoid re-replication are basically to avoid MCM complex re-loading on the 
chromatin. In developing eukaryotes, MCM proteins are more abundant in tissues 
undergoing rapid cell divisions. Although there are no evidences of a direct role of 
MCMs in cancer occurrence, these observations may suggest that increasing the effective 
concentration of the MCM complex, or deregulating their normal cycle on the DNA, may 
result in the activation of a larger set of replication origins. Is c-Myc the “deregulating” 
element? In yeast it has been demonstrated that deregulation in the level of a single Mcm 
leads to genomic instability (Liang et al., 1999), since Mcm4,6 and 7 are reported as 
transcriptional targets in c-Myc database, by analogy, it is thus conceivable that 
deregulated c-Myc may also cause genomic instability. Our results show a direct 
interaction between c-Myc and MCMs that is stable along the cell cycle. We also show 
that these proteins are loaded on the chromatin at the same time, and data from the 
glycerol gradient purification of the complex suggest the possibility that c-Myc interacts 
with other component of the pre-replication complex (pre-RC). Among them Cdt1 and 
Cdc6 that are necessary to recruit the MCM complex in order to license the origins. It is 
tempting to hypothesize that c-Myc is somehow involved in the loading of the ring 
helicase on the chromatin, or at least that in pathologic conditions c-Myc overexpression 
can lead somehow to a deregulated amount of MCM complex on the origin or override 
their normal cycling. Further investigations are needed to verify these hypotheses that 
link c-Myc to origin firing and finally to genomic instability. Understanding the role of c-
Myc in these processes may help to explain the impressive (compare to a classical 
transcription factor) number of genes that have been found bound by c-Myc, and also its 
involvement in almost every form of tumors. 
 The work presented in this thesis, the c-Myc complex purification and the 
characterization of the interaction between c-Myc and the MCM complex is the starting 
point of a bigger project that aims to assign a role of c-Myc in replication that is the 
current interest of our lab. 
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CHAPTER IV 
Materials and Methods 
 
 
4.1 Cell lines and Culture condition 
293T are human embryonic kidney fibroblasts expressing SV 40 large T antigen that 
allows expression of plasmids with SV 40 origin. H1299 are p53-null human lung 
carcinoma cell line. MCF7 and T47D cell lines originate from human breast carcinoma 
pleural effusions. These cells were maintained in Dulbecco's modified Eagles medium 
(GIBCO) supplemented with 10% fetal bovine serum, penicillin (100 I.U./ml), and 
streptomycin (100 µg/ml).  
Colon carcinoma cell line SW48 and Burkitt's lymphoma cell lines Raji, Ramos were 
maintained in Iscove modified Dulbecco medium (GIBCO) supplemented with 10% fetal 
bovine serum, penicillin (100 I.U./ml), and streptomycin (100 µg/ml).  
The H1299 cell line stably expressing the full length c-Myc HA/Flag double tagged 
(H/HF2), was already available in the lab. 
 
4.2 Plasmid preparation 
Plasmids expressing the wild-type proteins used in this work, their tagged form or 
mutans, were generated by PCR sequence amplification form a library of Ramos cDNA 
and insertion in appropriated vecrtor as listed:  
 
pcDNA3 (Invitrogen): 
Mcm2, Mcm7 
Mcm2-HA, Mcm3-HA, Mcm4-HA, Mcm5-HA, Mcm6-HA, Mcm7-HA 
Mcm7 (1-146)-HA, Mcm7 (146-642)-HA, Mcm7 (146-719)-HA,  
Mcm7 (1-145)-HA, Mcm7 (146-642)-HA, Mcm7 (643-719)-HA 
Myc, Myc-Flag, Myc-HA 
Myc∆(1-45)-Flag, Myc∆(6-94)-Flag, Myc∆(6-151)-Flag, Myc∆(92-151)-Flag, 
Myc∆(143-237)-Flag, Myc∆(237-302)-Flag, Myc∆(301-395)-Flag 
Myc (1-129)-HA, Myc (1-150)-HA, Myc (1-328)-HA, Myc (151-353)-HA, 
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Myc (151-340)-HA, Myc (151-439)-HA, Myc (262-439)-HA, Myc(341-439)-HA 
pProEX HT (Life Technologies): 
Max 
Mcm2-HA, Mcm3-HA, Mcm4-HA, Mcm5-HA, Mcm6-HA, Mcm7-HA 
pGEX-4T (Amersham Bioscience): 
Max 
Myc(1-42), Myc(1-103), Myc(1-143), Myc(1-228), Myc(151-340), Myc(262-
439), Myc(341-439) 
Mcm7(1-719), Mcm7(1-145), Mcm7(146-642), Mcm7(643-719) 
 
PCR reactions were performed with Platinum Pfx DNA Polymerase (Invitrogen). Oligo 
sequences are available upon request. 
The integrity of all the plasmid used in this study was confirmed by sequence analysis 
 
4.3 Transfection 
The cells were transfected according a modification of the calcium phosphate 
precipitation technique described by Wigler et al. (1977). Briefly, one day before 
transfection, 2.3 × 106 293T cells, or 2× 106 H1299 cells, were seeded in 10-cm dish. One 
day later, a calcium-phosphate precipitation of DNA (20-25 µg of plasmid) was prepared 
and added to the medium covering the cell. The cells were incubated for 24 hours, and 
the medium was replaced. After 40 hours from the transfection the cells were harvested. 
 
4.4 Reporter assay 
293T cells in 6 cm dishes were co-transfected, according to the calcium-phosphate 
method previously described, with different combination of plasmid as reported in Figure 
25. As reporter gene we used a construct carrying the Luciferase gene under the control 
of 800br of the tert promoter (TERTLuc800) described in Wu KJ et al., 1999. 48 hours 
after the transfection, cells were harvested and lysed. Lyses of the cells and reporter assay 
were performed using the Promega Dual-Light system, according to the manufacturer 
instructions. 
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4.5 Protein extracts preparations 
Nuclear extract preparation for complex purification 
The cells were treated with MG132 (Sigma) 100µM for 4 hours, harvested in cold PBS 
(Dulbecco’s Phosphate Buffered Salt Solution, Cellgro), and spun down by centrifugation 
at 2.500 rpm for 5 min at 4°C (Eppendorf centrifuge 5810 R). The cellular pellet was 
resuspended in brf A (10mM KCl, 10mM HEPS pH 7.9, 0.1 EDTA, 10mM NaF, 10mM 
β-glycerolphosphate, 1,5 Na3VO4, 1mM PMSF, Protease Inhibitors cocktail from Sigma) 
and the cell were allowed to swell on ice for 15 min. Then were vortexed vigorously and 
spun down at 3000 rpm 5 min at 4°C. The supernatant including the cytosolic fraction 
was discarded and the nuclear pellet resuspended in approximately 10 fold brf C (20mM 
HEPES pH 7.9, 400mM NaCl, 1mM EDTA, 10mM NaF, 10mM β-glycerolphosphate, 
1,5 Na3VO4, 1mM PMSF, Protease Inhibitors). The final concentration 400mM NaCl 
was adjusted, according to the size of the pellet, by adding 5M NaCl. After adding NP-40 
to a final concentration of 0.2%, the samples were vortexed on ice for 1 hr. Bfr D (20mM 
HEPES ph 7.9, 1mM EDTA 10mM NaF, 10mM β-glycerolphosphate, 1.5 Na3VO4, 1mM 
PMSF, Protease Inhibitors) was added to adjust the salt concentration to 300mM. The 
samples were ultracentrifuged at 25,000 rpm fot 1.5 hr at 4°C (Sorvall T-647.5) and the 
supernatant filtered trough 0.45 µm (NALGENE)  
Whole cell extract  
293T or H1299 were harvested and washed in cold PBS. After centrifugation the cellular 
pellet was resuspended in bfr F (10mM Tris pH 7.05, 150mM NaCl, 30mM Na 
Pyrophosphate, 50mM NaF, 5µM ZnCl2, 1% Triton, 0.1mM Na3VO4, 1mM PMSF, 
Protease Inhibitors) and vortexed 30 min on ice. The lysates were then centrifugated at 
14.000 rpm for 30 min at 4°C .  
Chromatin fraction extract 
This protocol is a modification of the one reported in Mendez & Stillman, Mol Cell Biol 
2000. 
The cells are harvested in cold PBS. After centrifugation, the cellular pellet was 
resuspended in CSK bfr (10mM HEPES pH 7.9, 100mM NaCl, 1.5mM MgCl2, 300mM 
Sucrose, 50mM NaF, 0.1mM Na3VO4, PMSF, Protease Inhibitors) and spun down to 
wash. The cell were resuspended in CSK-Triton bfr (CSK + 0.5% Triton X100) and were 
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incubated 10 min on ice. The samples were spun down at 5000 rpm for 3 min at 4°C. The 
supernatant contains cytoskeleton, membranes, cytosol and nucleoplasmic proteins. The 
pellets were resuspended in EDTA-EGTA bfr (20mM HEPES-Na pH 8.0, 3mM EDTA, 
0.2mM EGTA, 1mM DTT, PMSF, Protease Inhibitors) and were incubated 4 min on ice. 
The samples were spun down at 5000 rpm for 3 min at 4°C. The supernatants were 
discarded. The pellet is the Chromatin enriched fraction. 
 
4.6 Antibodies 
For Western Blot analysis and immunoprecipitations, anti-Max (C-17) and anti-Myc 
(N262) polyclonal antibodies were purchased from Sancta Cruz. Anti-Mcm2 and anti-
Mcm4 polyclonal antibodies were purchased from BD Pharmigene. Polyclonal anti-
Mcm3 and monoclonal anti-Mcm6 antibodies were purchased from BD Transduction 
Laboratories. Anti-Mcm5 and anti-Mcm7 monoclonal antibody were purchased from Lab 
Vision. Anti-cdc6 monoclonal antibody was purchased from Upstate. Anti-Cdt1 antibody 
was kindly provided by Hideo Nishitani. Anti-Flag monoclonal antibody was purchased 
from Sigma. Anti-HA High Affinity (3F10) Rat monoclonal antibody was purchased 
from Roche. Anti-phospho-H3 histone on Ser10 antibody was purchased from Upstate. 
To immunoprecipitate endogenous c-Myc from cell lysates was used anti-Myc rabbit 
polyclonal antibody purchased from Upstate. 
In the Immuno-colocalization assay, anti-mouse FITC-conjugated antibody and 
streptavidin-Cy3 antibody were purchased from Jackson ImmunoResearch, while the 
anti-rabbit biotin-conjugated was purchased from Vector. 
 
4.7 Immunoprecipitation 
The protein extracts were precleared with protein G Sepharose 4 fast flow (Amersham) 
for 2 h at 4°C. After removing the beads, each mg of protein extract was incubated O.N. 
at 4°C with 2-5 µg of specific antibody for the protein of interest. The day after the 
samples were centrifuged for 10 min at 14,000 rpm, 4°C. The antibodies were 
immunoprecipitated by incubating the supernatants with protein G Sepharose 4 fast flow 
for 2 h at 4°C. The beads were washed 5 times for 5 min each at 4°C and resuspended in 
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SDS loading bfr (10% glycerol, 60m Tris-HCl pH 6.8, 2% SDS, 0.025% BrPh Blue, 
50mM DTT). 
For immunoprecipitation of Flag/HA-tagged proteins: 
Flag conjugated M2-agarose beads (Sigma) were added in appropriate amount, according 
to manufacturer instructures, to cell lysates and left over night (O.N.) rotating at 4°C. The 
day after the beads were collected by centrifugation and the supernatant was discarded. 
The beads were washed 5 times in the same buffer used for the binding, and the proteins 
were eluted from the beads by affinity competition using Flag peptide (Sigma) 0.5µg/µl 
O.N. at 4°C. 
For HA-tagged proteins were used Monoclonal Anti-HA Agarose Conjugate (Sigma) for 
immunoprecipitation and HA peptide (Sigma) 1µg/µl, 4 h - O.N. at 4°C 
 
4.8 Cell synchronization 
Double block Thymidine/Mimosine (G1/S) 
After overnight incubation with 2 mM thymidine (Sigma) H1299 cells were washed with 
fresh medium without thymidine and released for 10 h. then the cells were subjected to 
the second block with 2 mM thymidine + 400 µM  Mimosine (Sigma) for 14 h. The cells 
where washed twice in PSB and fixed with 4% paraformaldehyde in PBS for 20 min at T 
room.  
Double block Thymidine/Nocodale (mitosis) 
The cells were first trated O.N. with Thymidine for a first block. Then they were washed 
with PBS and incubated in fresh medium with 50ng/ml Nocodazole (Sigma) for 12 h. 
Loosely attached, rounded mitotic cells were shaken off by gently knocking the plate. 
The cells were counted, replated in same amount abd sampled at different time points. 
Fractionated protein extracts were obtained according the CSK buffer extraction 
described above. 
Propidium iodide staining for FACS analysis 
The cells were harvested and resuspended in PBS. In order to fix them, absolute ethanol 
was added drop by drop to the cells until a final concentration 70%. The samples were 
left O.N. at 4°C. Before FACS analysis wash the cells twice in PBS and stained O.N. at 
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4°C in PBS + 15mM Propidium Iodade + 1mM sodium citrate + 280µg/ml RNase. The 
day after the cell were washed, resuspended in PBS and analysed by flow cytometry. 
 
4.9 Immunofluorescence 
H1299 cells were seeded on cover slips and were synchronized with a double block 
thymidine/mimosine. After the second block, the cells were washed twice with PBS, and 
treated with CSK-Triton bfr for 5 min on ice. The nucleoplasmic, cytosolic and 
cytoskeleton proteins were washed away with PBS and then the cells were fixed. The 
cellular membranes were permeabilized with PBS + 0.2% Triton for 10 min at T room. 
After washing with PBS the cells were blocked with PBS + 0.1% Tween + 3% BSA for 1 
h at T room. The cells were incubated 2 h in the same blocking brf with antibody against 
c-Myc and Mcm7, 1:100 N262 (Sigma) and 1:150 CDC47 / MCM7 Ab-2 (Lab Vision) 
respectively. Then the cell were washed three times with PBS for 5 min and incubated 
with the secondary antibody for 45 min at T room in blocking bfr. For Mcm7was used a 
mouse secondary antibody (Jackson ImmunoResearch) conjugated with FITC diluted 
1:200, and for c-Myc a rabbit secondary antibody (Vector) biotin-conjugated diluted 
1:400. After incubation the cells were washed three times in PBS to detect c-Myc was 
used streptavidin Cy3 (Jackson ImmunoResearch) 1:500 in blocking bfr for 15 min. The 
cells were washed three times in PBS and the cover slips mounted on glass for 
immunofluorescence analysis. 
 
4.10 Glycerol gradient 
30-60% glycerol gradient in BC300 buffer (300mM NaCl, 20% glycerol, 20mM Tris-
HCl ph 7.9, 0.1% NP-40, 1mM PMSF) was generated with a gradient former in 5ml 
Backman ultracentrifuge tube. 250µl of sample (corresponding to the c-Myc protein 
complex purified from 12 15cm-dishes of H/HF2 cell line) were layered on the top of the 
tube. The tube was ultracentrifuged in a Backman swinging bucket rotor SW 50.1 at 
48,000 rpm for 20 h at 4°C. From the bottom of the tube, 200µl fractions were collected 
and 1/3 of them run on SDS-PAGE for western blot analysis. 
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4.11 SMART gel filtration chromatography system  
The complex of proteins associates with c-Myc was separated directly by a Precision 
Column PC 3.2/3.0 pre-pached with Superose 6 (Pharmacia Biotech). This is a highly 
cross-linked, 6% agarose-bases medium, optimized for high performance gel filtration. 
 
4.12 Recombinant proteins purification and GST-pull down 
BL21 bacteria were transformed with prokaryotic expression vector carrying the cDNA 
of the protein of our interest. Singles colonies were inoculated in 20 ml LB medium with 
100 µg /ml Ampicillin which was placed in a 37°C shaker overnight. The next day these 
starter cultures were used to inoculate 200 ml LB medium which contained 100 µg/ml 
Ampicillin. Protein induction was carried out with the addition of 0.5mM IPTG after the 
cells reached an OD590 of 0.4 and incubated O.N. at 30°C. Bacteria were spun down at 
5,000 rpm for 10 min at 4°C and resuspended in PBS + 1mM PMSF + 5mM β-
mercaptoethanol. After adding Sarkosil to a final concentration of 1.5%, the samples 
were sonicated on ice for 15 min with 2 sec pulses every 2 sec. Triton to final 
concentration of 1% was added to the lysates, and the NaCl concentration increased up to 
250mM. The samples were vortexed vigorously and put rotating 30 min at 4°C. The 
lysates were centrifuged at 25,000 rpm for 30 min at 4°C and then passed through 
0.45µm filter (NALGENE). 
GST-fusion proteins were purified incubating the extracts O.N. with beads Glutathion 
Sepharose 4B (Amersham Biosciences). The day after the beads were washed 3 times in 
the same buffer and twice in BC100 buffer (100mM NaCl, 20% glycerol, 20mM Tris-
HCl ph 7.9, 0.1% NP-40, 1mM PMSF). The protein bound to the beads were eluted 
incubating the beads in BC100 + 20mM glutation O.N. at 4°C. 
His-fusion proteins were purified incubating the extracts with Ni-NTA resin (Life 
Technologies) according to the manufacturer instructions. 
HA-Myc-Flag recombinant protein was purified according a double step strategy: Flag-
conjugated M2 Agarose beads were added to the bacteria lysate, and incubated O.N. at 
4°C. The beads were washed 3 times in the same buffer and twice in BC100 buffer. The 
Flag-bound proteins were eluted in bfr BC100 + Flag peptide 0.5µg/µl 4 h at 4°C. HA-
agarose beads were added to the eluted proteins and incubated O.N. at 4°C. The day after, 
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the beads were washed 5 times with BC100 buffer and the HA-bound proteins were 
eluted with bfr BC100 + HA peptide 1µg/µl, 4 h - O.N. at 4°C. 
After purification the recombinant proteins were tested on SDS-PAGE and Blue 
Comassie staining in order to estimate the amount and presence of possible degradation 
product. 
For in vitro pull down experiment, the protein were incubated 2 h at 4°C in binding bfr 
(50mM Tris-HCl pH 7.4, 200-300mM KCl, 1mM MgCl2, 1mM DTT, 0.2% NP-40). 
According to the bait we were using, M2 beads, Glutation Sepharose 4B, or Ni-NTA 
beads were added to the reaction mix and incubated 1h at 4°C. The beads were washed 
and resuspended in SDS loading dye. The proteins were separated by SDS-PAGE and 
detected by Western Blot. 
 
4.13 Oligonucleotides pull down 
293T were transfected 48 h before in 10-cm dish according to the technique already 
described. 
The cell were harvested and lysed in bfr F. The protein extracts (1-2 mg) were incubated 
1-2H with 20-40 µL W/v of Streptavidin-Agarose beads (Sigma) as preclearing step. 
Subsequently were inqubated with the 10µg of the biotinylated probe in presence of 
100µg of poly dI-dC (Sigma), as competitor, O.N. at 4°C. The samples were spun down 
at 1400 rpm for 15 min at 4°C. The supernatants were transferred in new tubes with 10-
20µl w/v Streptavidin-Agarose beads, prewashed and equilibrated in bfr F, and were 
incubated for 30 min at 4°C. The supernatants were collected as “unbound fractions” and 
the beads were washed 5 times with bfr F and then resuspended in SDS loading buffer. 
Probe preparation 
Oligos of 38bp encompassing the BN51-intron1 E-box (GenBank accession no. 
AF142779), described by Amati and coworkers (Greasley et al, Nucleic Acids Res. 
2000), were synthesized. The mutated probe carries a single point mutation in the E-box: 
CACGTG to TACGTG. Only the forward one was 5’ biotinylated. For the annealing 
equimolar amounts of the two oligos were diluted in annealing buffer (20mM Tris pH 
7.9, 50mM NaCl, 1mM EDTA), boliled at 95°C for 5 min and then gradually cooled 
down.  
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